attachment
attachment

Answer them for my university exam

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File

Pathology Paper I - Complete Exam Answers


SECTION: Injury, Cellular Adaptations and Cellular Aging


SN 1. Types of Calcification; Dystrophic vs Metastatic Calcification

Types of Pathologic Calcification

Pathologic calcification is the abnormal tissue deposition of calcium salts, together with smaller amounts of iron, magnesium, and other mineral salts. There are two major forms:
  1. Dystrophic calcification
  2. Metastatic calcification

Dystrophic Calcification

  • Definition: Deposition of calcium salts in dead or dying (necrotic) tissues, despite normal serum calcium levels and no derangement in calcium metabolism.
  • Mechanism: The underlying disease damages cell membranes, leading to calcium influx. Phospholipid-rich cell membranes in necrotic cells act as nucleation sites. Membrane-bound vesicles concentrate calcium and phosphate, initiating crystalline hydroxyapatite formation.
  • Sites: Areas of coagulative, caseous, or liquefactive necrosis; atheromas of advanced atherosclerosis; aging or damaged heart valves (calcific aortic stenosis); tuberculous lymph nodes (may convert to stone); fat necrosis.
Histology (H&E): Calcium salts appear basophilic, amorphous, granular, sometimes clumped. Can be intracellular or extracellular. Over time, lamellated configurations called psammoma bodies may form (e.g., in papillary thyroid carcinoma, meningioma, serous cystadenoma of ovary).
Dystrophic calcification of aortic valve
Dystrophic calcification of the aortic valve - Robbins Pathology

Metastatic Calcification

  • Definition: Deposition of calcium salts in normal, otherwise healthy tissues, almost always resulting from hypercalcemia due to a disturbance in calcium metabolism.
  • Causes of hypercalcemia:
    • Hyperparathyroidism (primary or secondary)
    • Destruction of bone (metastases, multiple myeloma, Paget disease)
    • Vitamin D-related disorders (intoxication, sarcoidosis)
    • Renal failure
    • Milk-alkali syndrome
  • Sites: Interstitial tissues of gastric mucosa, kidneys (nephrocalcinosis), lungs, systemic arteries, pulmonary veins, and cornea (all sites that lose acid, allowing pH to rise, which favors calcium precipitation).

Differences: Dystrophic vs Metastatic Calcification

FeatureDystrophicMetastatic
Site of depositionNecrotic/dead tissueNormal viable tissue
Serum calciumNormalElevated (hypercalcemia)
Calcium metabolismNormalDisturbed
Underlying causeLocal tissue necrosis/injurySystemic calcium disorder
ExamplesTB lymph node, atheroma, damaged valvesHyperparathyroidism, renal failure
Clinical significanceMarker of prior injury/necrosisIndicates systemic metabolic disease
Serum phosphateNormalOften elevated

SN 2. Apoptosis - Definition, Examples, Morphological Changes, Mechanisms, Physiological and Pathological Causes

Definition

Apoptosis is a pathway of cell death that is induced by a tightly regulated suicide program in which cells destined to die activate enzymes (caspases) that degrade their own nuclear DNA and cytoskeletal and cytoplasmic proteins. The plasma membrane remains intact, but its structure is altered, so the dying cell becomes a target for phagocytosis by macrophages or neighboring cells. The dead cell is rapidly cleared before its contents have leaked out, so apoptotic cell death does not elicit an inflammatory reaction.

Morphological Changes

  1. Cell shrinkage - the cell is smaller; cytoplasm is dense; organelles are more tightly packed
  2. Chromatin condensation (pyknosis) - chromatin aggregates peripherally under the nuclear membrane into dense masses
  3. Nuclear fragmentation (karyorrhexis) - the nucleus breaks up into two or more fragments
  4. Cytoplasmic blebs - the cell surface shows irregular budding
  5. Apoptotic body formation - blebs pinch off to form membrane-bound apoptotic bodies, which may contain fragments of nucleus and/or cytoplasm
  6. Phagocytosis - apoptotic bodies are rapidly eaten by macrophages or neighboring cells. No inflammation occurs because membrane integrity is preserved.

Mechanisms (Pathways)

1. Intrinsic (Mitochondrial) Pathway:
  • Triggered by: DNA damage, oxidative stress, ER stress, growth factor withdrawal
  • Key players: BCL2 family proteins
    • Anti-apoptotic: BCL2, BCL-XL, MCL1 (keep mitochondrial outer membrane impermeable)
    • Pro-apoptotic: BAX, BAK (permeabilize the membrane)
    • BH3-only sensors: BAD, BIM, BID, PUMA, NOXA (detect stress, activate BAX/BAK)
  • When stress signals dominate, BAX/BAK oligomerize in the outer mitochondrial membrane → cytochrome c leaks into cytosol
  • Cytochrome c + APAF-1 → forms the apoptosome → activates caspase-9 (initiator) → activates caspase-3 (executioner) → cell death
2. Extrinsic (Death Receptor) Pathway:
  • Triggered by: Fas ligand binding to Fas (CD95), TNF binding to TNFR1
  • Fas-FasL interaction → recruitment of FADD (Fas-associated death domain) → activates caspase-8 (initiator) → activates caspase-3 → cell death
  • Cross-talk: Caspase-8 cleaves BID (a BH3-only protein) → truncated BID (tBID) activates the mitochondrial pathway, amplifying the signal
3. Caspase-Independent Pathways (e.g., via AIF - apoptosis-inducing factor from mitochondria)

Physiological Causes (Normal Events)

  1. Programmed cell death during embryogenesis (organogenesis, limb development - interdigital web removal)
  2. Involution of hormone-dependent tissues after hormone withdrawal (e.g., endometrial shedding during menstrual cycle; post-lactation breast involution)
  3. Cell deletion in proliferating cell populations to maintain constant cell numbers (e.g., intestinal crypt cells)
  4. Elimination of self-reactive lymphocytes in the thymus and periphery (negative selection)
  5. Death of immune effector cells (cytotoxic T lymphocytes) after serving their protective role

Pathological Causes (Disease States)

  1. DNA damage - radiation, cytotoxic drugs causing unrepaired double-strand DNA breaks
  2. Viral infections - hepatitis B and C (apoptosis of infected hepatocytes); also used by some viruses to spread
  3. Accumulation of misfolded proteins - ER stress (e.g., in neurodegenerative diseases like Alzheimer, Parkinson)
  4. Obstruction of ducts - pancreatic duct, salivary duct obstruction leads to apoptosis of gland cells
  5. Cell injury in diseases - myocardial infarction, neurodegenerative diseases
  6. Tumor regression after chemotherapy/radiotherapy

SN 3. Metaplasia, Hypertrophy, Hyperplasia, and Atrophy - Definitions with Examples

Atrophy

Definition: Reduction in the size of a cell, caused by the loss of cell substance. When enough cells are affected, the entire tissue or organ shrinks. Atrophy = decreased cell size and number.
Types:
  • Physiologic: Normal aging (brain atrophy after age 60)
  • Pathologic: Denervation atrophy, pressure atrophy, disuse atrophy, inadequate nutrition, loss of endocrine stimulation, ischemia
Examples: Shrinkage of the uterus after menopause; muscle wasting in a limb in a plaster cast; brain atrophy in senility; thyroid gland atrophy after loss of TSH stimulation.
Mechanisms: Decreased protein synthesis + increased protein degradation (via ubiquitin-proteasome pathway). Autophagy also contributes.

Hypertrophy

Definition: Increase in the size of cells and consequently the organ, without an increase in cell number. The enlarged cells have more structural components. Occurs in cells that cannot undergo division (permanent cells like cardiac and skeletal muscle).
Types:
  • Physiologic: Pregnant uterus (smooth muscle hypertrophy due to estrogen); skeletal muscle in bodybuilders
  • Pathologic: Cardiac hypertrophy in hypertension or aortic stenosis (left ventricular hypertrophy)
Mechanism (cardiac): Increased workload → mechanical sensors activate PI3K/AKT pathway → transcription factors (GATA4, NFAT, MEF2) → increased contractile protein synthesis + switch from α-myosin to β-myosin heavy chain (slower, more energy-efficient contractions).
Examples: Left ventricular hypertrophy in hypertension; biceps enlargement in manual workers; right ventricular hypertrophy in cor pulmonale.

Hyperplasia

Definition: Increase in the number of cells in a tissue or organ, resulting in increased mass. Can occur only in tissues containing cells capable of dividing. Often occurs along with hypertrophy.
Types:
  • Physiologic: Hormonal (breast enlargement during pregnancy); compensatory (liver regeneration after partial hepatectomy)
  • Pathologic: Endometrial hyperplasia (excess estrogen); BPH (benign prostatic hyperplasia due to DHT); psoriasis (epidermal hyperplasia)
Mechanism: Growth factors (e.g., EGF, HGF) or hormones stimulate cell cycling via G1-to-S phase transition. Stem cells are activated to produce new cells.
Examples: Thyroid hyperplasia in iodine deficiency (goiter); adrenal cortical hyperplasia in ACTH excess; epidermal hyperplasia in chronic skin irritation.

Metaplasia

Definition: A reversible change in which one adult cell type (epithelial or mesenchymal) is replaced by another adult cell type, usually in response to chronic irritation or pathologic stimulus.
Types:
  • Columnar to squamous (most common): Respiratory epithelium in smokers; cervical ectropion with squamocolumnar junction transformation; stones in ducts (salivary, pancreatic, bile ducts)
  • Squamous to columnar: Barrett esophagus - esophageal squamous epithelium replaced by intestinal columnar cells due to chronic GERD (risk: adenocarcinoma)
  • Connective tissue: Myositis ossificans (bone formation in muscle after intramuscular hemorrhage)
Mechanism: Not a change in phenotype of existing cells; rather, reprogramming of local tissue stem cells to differentiate along a different lineage, driven by signals in the cell's environment (e.g., vitamin A signaling, chronic irritation).
Significance: Metaplastic epithelium is more resistant to the irritant stimulus, but at a cost (loss of normal function, e.g., loss of cilia in respiratory mucosa). Persistent stimuli can lead to malignant transformation (e.g., squamous cell carcinoma in smokers' bronchi; adenocarcinoma in Barrett esophagus).

SN 4. Free Radicals and Free Radical-Induced Cell Injury

Definition

Free radicals are chemical species that have a single unpaired electron in an outer orbit, making them highly unstable and reactive. They attack and modify adjacent molecules (proteins, lipids, carbohydrates, nucleic acids) through autocatalytic chain reactions.
Reactive oxygen species (ROS) are the most important free radicals in cell injury: superoxide (O2•-), hydrogen peroxide (H2O2), hydroxyl radical (•OH).

Generation of Free Radicals

  1. Normal mitochondrial respiration - reduction of O2 generates small amounts of O2•-, H2O2, and •OH as byproducts
  2. Ionizing radiation - hydrolyzes water into •OH and H• radicals
  3. Activated leukocytes during inflammation - NADPH oxidase generates O2•- (respiratory burst)
  4. Enzymatic metabolism of drugs/chemicals - e.g., CCl4 → •CCl3 (toxic radical)
  5. Transition metals (iron, copper) - Fenton reaction: H2O2 + Fe2+ → Fe3+ + •OH + OH- (most damaging radical)
  6. Reperfusion of ischemic tissue - burst of ROS generation

Removal / Antioxidant Defense

  • Superoxide dismutase (SOD): converts O2•- to H2O2
  • Catalase: breaks down H2O2 to H2O + O2
  • Glutathione peroxidase: reduces H2O2 and lipid peroxides
  • Vitamins E, A, and C - antioxidants that scavenge free radicals
  • Ceruloplasmin, transferrin - sequester iron/copper to prevent Fenton reaction

Mechanisms of Free Radical-Induced Cell Injury

1. Lipid peroxidation of membranes:
  • •OH attacks double bonds in polyunsaturated fatty acids of cell membranes
  • Creates lipid peroxides and new free radicals (autocatalytic chain reaction)
  • Results in: increased membrane permeability, loss of membrane potential, organelle dysfunction
2. Oxidative modification of proteins:
  • Oxidation of amino acid side chains
  • Covalent cross-linking of proteins (disulfide bonds)
  • Oxidation of protein backbone → enzyme active site disruption
  • Enhanced proteasomal degradation of misfolded proteins
3. DNA lesions:
  • Single- and double-strand breaks in DNA
  • Cross-linking of DNA strands, adduct formation
  • Implicated in: cell aging, malignant transformation
4. Activation of apoptosis:
  • Free radicals can trigger the intrinsic mitochondrial apoptotic pathway (at lower doses)
  • At higher doses: necrosis predominates

Pathologic Conditions Caused by Free Radical Injury

  • Ischemia-reperfusion injury (MI, stroke)
  • Chemical and drug toxicity (CCl4 hepatotoxicity)
  • Radiation injury
  • Oxygen toxicity (in premature neonates - retrolental fibroplasia, BPD)
  • Aging
  • Atherosclerosis (oxidized LDL)
  • Carcinogenesis

LAQ 1. Necrosis - Definition, Types, Caseous Morphology, Coagulative vs Liquefactive Necrosis

Clinical Scenario Link:

  • Diabetic patient with pale, dry leg ulcer = coagulative necrosis (ischemic gangrene)
  • TB patient with cheesy lung lesion = caseous necrosis
  • Stroke patient with brain liquefaction = liquefactive necrosis

Definition of Necrosis

Necrosis is a form of cell death that results from exogenous perturbations such as infection, toxins, or trauma. It is characterized by denaturation of intracellular proteins, enzymatic digestion of organelles and cellular contents, and loss of membrane integrity, resulting in leakage of cellular contents. This provokes a local inflammatory response.

Morphological Features Common to All Necrotic Cells

  • Cytoplasm: Eosinophilia (due to denatured cytoplasmic proteins binding eosin; loss of RNA)
  • Nuclear changes (3 patterns):
    • Karyolysis - basophilia fades due to DNase activity
    • Pyknosis - nuclear shrinkage and increased basophilia (chromatin condenses)
    • Karyorrhexis - fragmentation of pyknotic nucleus
    • Over 1-2 days, nucleus totally disappears
  • Cytoplasm: Vacuolated, moth-eaten appearance; myelin figures (phospholipid precipitates) may form

Types of Necrosis

TypeKey FeatureExample
CoagulativeArchitecture preserved; firm, eosinophilic "ghost" cellsKidney/heart/spleen infarct
LiquefactiveComplete dissolution; fluid-filled cavityBrain infarct; pyogenic abscess
CaseousCheese-like; granuloma with central necrosisTuberculosis
FatChalky white deposits (saponification)Acute pancreatitis; breast trauma
FibrinoidPink fibrin-like material; immune complex depositionVasculitis, malignant hypertension
GangrenousClinical term; dry = coagulative; wet = liquefactiveDiabetic foot

Morphology of Caseous Necrosis

Gross: The necrotic area has a soft, friable (cheese-like), yellow-white appearance - like cottage cheese or dry crumbled cheese. This appearance is called "caseous" (from Latin caseus = cheese).
Microscopic: The necrotic focus is enclosed within a rim of inflammatory granuloma tissue consisting of:
  • Central area: acellular, granular, eosinophilic debris with loss of all architectural tissue details (unlike coagulative necrosis, ghost outlines are NOT preserved)
  • Surrounding zone: epithelioid macrophages (activated macrophages with abundant pale cytoplasm)
  • Langhans giant cells (multinucleated cells formed by fusion of macrophages, with nuclei arranged in a horseshoe/peripheral pattern)
  • Peripheral lymphocyte infiltration
  • Occasional plasma cells
  • Over time: dystrophic calcification may occur in the necrotic center
This entire structure (caseation + epithelioid cells + giant cells + lymphocytes) = granuloma
Caseous necrosis in tuberculosis
Caseous necrosis in tuberculosis of the lung - Robbins Pathology

Coagulative vs Liquefactive Necrosis (in Detail)

Coagulative Necrosis:
  • Mechanism: Denaturation of both structural proteins AND enzymes (proteolytic enzymes are denatured, so they cannot digest the dead cells)
  • Result: Cell architecture is preserved for days - "ghost outlines" or "tombstone cells" visible microscopically (cell shape preserved but nucleus gone)
  • Gross: Firm, pale, dry, well-demarcated area. In the heart: yellow-white area. In kidney: wedge-shaped infarct.
  • Microscopy: Intensely eosinophilic cells with indistinct or absent nuclei; preserved cellular outlines; inflammatory infiltrate at periphery
  • Cause: Ischemia (obstruction of blood supply to all organs except the brain)
  • Clinical example: Myocardial infarction, renal infarct, splenic infarct, pale infarct of any solid organ. The 58-year-old diabetic's ischemic leg ulcer = dry gangrene = coagulative necrosis.
Coagulative necrosis
Coagulative necrosis: wedge-shaped renal infarct - Robbins Pathology
Liquefactive Necrosis:
  • Mechanism: Enzymatic digestion dominates - dead cells are rapidly digested by their own hydrolases and by leukocyte-derived enzymes. Entire tissue is liquefied.
  • Result: Tissue is completely dissolved; the area is converted into a liquid viscous mass, eventually forming a cyst-like cavity
  • Gross: Soft, fluid-filled cavity
  • Microscopy: Complete loss of cellular architecture; only fluid, debris, and leukocytes visible
  • Causes:
    • Brain ischemia/infarction - neurons are very rich in hydrolytic enzymes, and the brain has poor structural protein support, so liquefaction always occurs (even with ischemia - unlike other organs)
    • Bacterial (pyogenic) infections - neutrophil enzymes liquefy the tissue → pus (the liquid mass of liquefactive necrosis is called "pus" in infections)
  • Clinical example: Brain infarct (stroke) - forms a fluid-filled cavity (the 3rd patient); pyogenic abscess (lung abscess, brain abscess)
Liquefactive necrosis
Liquefactive necrosis: brain infarct - Robbins Pathology

LAQ 2. Atrophy: Definition, Morphology and Causes of Brown Atrophy of the Heart

Definition of Atrophy

Atrophy is defined as a decrease in the size of a cell (and consequently the organ) resulting from loss of cell substance. Atrophy can occur as a result of a decreased workload, loss of innervation, diminished blood supply, inadequate nutrition, loss of endocrine stimulation, or aging.

Brown Atrophy of the Heart

Definition: Brown atrophy refers to cardiac atrophy accompanied by accumulation of lipofuscin pigment (wear-and-tear pigment) within cardiomyocytes, giving the organ a brown color.

Gross Morphology

  • Heart is smaller than normal (reduced weight and size)
  • The organ has a brown discoloration (instead of normal red-brown)
  • "Tigroid" or nutmeg pattern may coexist if there is also chronic venous congestion
  • The coronary arteries may appear tortuous and dilated relative to the shrunken myocardium
  • Cut surface shows smaller, denser myocardial fibers

Microscopic Morphology

  • Cardiomyocytes are reduced in size with smaller, darker nuclei
  • Lipofuscin granules are visible as yellow-brown, perinuclear pigment granules within the cytoplasm (best seen with Sudan black or periodic acid-Schiff stain; also autofluorescent under UV light)
  • Lipofuscin = residual bodies from incomplete lysosomal digestion of damaged organelles (accumulated over a lifetime; the "wear and tear" pigment)
  • Myofibrils are reduced in number
  • Interstitial fibrosis may be present

Causes of Brown Atrophy of the Heart

  1. Advanced age (senile atrophy) - most common cause; the normal aging process leads to gradual cell loss and lipofuscin accumulation
  2. Cachexia (extreme malnutrition):
    • Advanced malignancy (cancer cachexia)
    • Severe chronic illness (chronic heart failure, TB, AIDS)
    • Starvation
  3. Prolonged bed rest / immobility - disuse atrophy from reduced cardiac workload
  4. Loss of endocrine stimulation - e.g., hypopituitarism
  5. Chronic ischemia with gradual loss of cardiomyocytes


SECTION: Immunopathology Including Amyloidosis


Immunopathology SN 1. Hypersensitivity Reactions - Classification + Type I in Detail

Definition

Hypersensitivity reactions are immune responses that are exaggerated or inappropriate against an antigen, causing tissue injury and disease. They can be triggered by environmental antigens (allergens), self-antigens (autoimmunity), or microbial antigens.

Classification (Gell and Coombs Classification)

TypeNameMechanismMediatorsExamples
Type IImmediate (Anaphylactic)IgE antibody + antigen → mast cell degranulationHistamine, leukotrienes, prostaglandinsAnaphylaxis, asthma, allergic rhinitis, urticaria
Type IICytotoxic (Antibody-mediated)IgG/IgM antibodies against cell-surface or matrix antigens → complement + ADCCComplement, NK cells, phagocytesHemolytic anemia, Goodpasture syndrome, blood transfusion reactions
Type IIIImmune Complex-mediatedAntigen-antibody complexes (IgG) deposited in tissues → complement + neutrophil activationComplement, neutrophilsSerum sickness, SLE, post-streptococcal glomerulonephritis, Arthus reaction
Type IVDelayed (Cell-mediated)Sensitized T lymphocytes (CD4+ or CD8+) react with antigenCytokines, cytotoxic T cellsContact dermatitis, tuberculin test, transplant rejection, Type 1 DM

Type I Hypersensitivity in Detail

Also called: Immediate hypersensitivity, IgE-mediated hypersensitivity, Anaphylactic hypersensitivity
Two phases:
  1. Sensitization phase (first exposure) - no symptoms
  2. Effector phase (re-exposure) - immediate reaction within minutes
Cellular and molecular mechanism:
Step 1 - Sensitization:
  • First exposure to antigen (allergen)
  • Antigen is processed by APCs (dendritic cells) and presented to CD4+ T helper cells
  • TH2 cells are activated → produce IL-4, IL-5, IL-13
  • IL-4 → induces B cell class switching to IgE
  • IgE binds to FcεRI receptors on mast cells and basophils (sensitization) - no symptoms yet
Step 2 - Re-exposure and Activation:
  • Re-exposure to the same allergen
  • Allergen cross-links IgE molecules on mast cell surface
  • Cross-linking triggers mast cell degranulation
Step 3 - Mast Cell Mediators:
Preformed (primary) mediators (released immediately):
  • Histamine - most important: vasodilation, increased vascular permeability, smooth muscle contraction, mucus secretion
  • Heparin - anticoagulant
  • Proteases (tryptase, chymase) - tissue damage, activate complement
Newly synthesized (secondary) mediators:
  • Leukotrienes (LTC4, LTD4, LTE4) - 1000x more potent than histamine in bronchoconstriction; prolonged action (the "slow-reacting substances of anaphylaxis" - SRS-A)
  • Prostaglandin D2 - bronchoconstriction, vasodilation
  • Platelet-activating factor (PAF) - platelet aggregation, bronchoconstriction
Cytokines (over hours):
  • IL-4, IL-5, IL-13 - promote TH2 response, IgE production, eosinophil recruitment
  • TNF-α - leukocyte recruitment
Step 4 - Late Phase Reaction (2-24 hours later):
  • Recruitment of eosinophils, basophils, neutrophils, TH2 cells
  • Eosinophils release: major basic protein (MBP), eosinophil peroxidase, eosinophil cationic protein
  • Cause prolonged tissue damage, edema, mucus secretion
  • Responsible for the "late-phase" bronchospasm in asthma
Clinical Manifestations:
Organ affectedManifestation
Systemic mast cell degranulationAnaphylaxis (life-threatening)
AirwaysAsthma (bronchoconstriction)
Nasal mucosaAllergic rhinitis (hay fever)
SkinUrticaria (hives), angioedema
GI tractNausea, vomiting, diarrhea
Treatment rationale:
  • Epinephrine (anaphylaxis) - reverses vasodilation and bronchospasm
  • Antihistamines (H1 blockers) - block histamine effects
  • Corticosteroids - reduce late-phase inflammation
  • Leukotriene antagonists (montelukast) - block LTD4 receptors

Immunopathology SN 2. Amyloidosis (Clinical Case: RA with Nephrotic Syndrome + Multiple Myeloma)

Clinical Scenario Analysis:

  • 58-year-old with rheumatoid arthritis + nephrotic syndrome + hepatosplenomegaly + firm spleen with pale tapioca-like nodules = Secondary (AA) amyloidosis
  • Patient with multiple myeloma with restrictive [cardiomyopathy implied] = Primary (AL) amyloidosis

Definition of Amyloidosis

Amyloidosis is a group of diseases characterized by the extracellular deposition of insoluble fibrillar proteins (amyloid) in tissues and organs, which impair normal function. All amyloid proteins share a common beta-pleated sheet (cross-beta) fibrillar structure that confers:
  • Resistance to proteolysis
  • Ability to bind Congo red dye (with apple-green birefringence under polarized light)
  • Positive staining with crystal violet (metachromasia) and thioflavin T/S (fluorescence)

Chemical Nature and Types

TypePrecursor ProteinClinical Association
AL amyloidImmunoglobulin light chains (lambda > kappa)Multiple myeloma, primary amyloidosis
AA amyloidSerum amyloid A (SAA) - acute phase reactantRheumatoid arthritis, chronic infections (TB, osteomyelitis), chronic inflammatory conditions
Aβ amyloidBeta-amyloid precursor protein (APP)Alzheimer disease
ATTR amyloidTransthyretinSenile systemic amyloidosis, familial amyloidosis
Aβ2MBeta-2 microglobulinLong-term hemodialysis

Classification

1. Primary (AL) Amyloidosis:
  • Associated with plasma cell dyscrasias (multiple myeloma, Waldenström)
  • Amyloid derived from immunoglobulin light chains (mostly lambda)
  • Deposits in: heart (restrictive cardiomyopathy), kidney, tongue (macroglossia), peripheral nerves, skin
2. Secondary (AA) Amyloidosis:
  • Associated with chronic inflammatory diseases (RA, IBD, ankylosing spondylitis, chronic infections like TB, osteomyelitis, bronchiectasis)
  • Amyloid derived from SAA (serum amyloid A, an acute-phase protein made by the liver)
  • Deposits in: kidneys (most common - nephrotic syndrome), liver, spleen, adrenals
3. Heredofamilial Amyloidosis:
  • Familial Mediterranean fever (AA type)
  • Familial amyloid polyneuropathy (ATTR from mutant transthyretin)

Morphology

Spleen:
  • Sago spleen - amyloid deposits in the follicles (white pulp) as small, grey/translucent nodules resembling sago grains (tapioca-like) - matches the case description
  • Lardaceous spleen - diffuse red pulp involvement; gives waxy, lard-like appearance, large rubbery spleen
Kidney:
  • Amyloid deposits in the glomerular mesangium and GBM → nephrotic syndrome (proteinuria, hypoalbuminemia, edema)
  • Kidney enlarged, pale, waxy
Liver:
  • Hepatomegaly; amyloid deposits in the space of Disse (between hepatocytes and sinusoids)
Heart (AL amyloidosis):
  • Restrictive cardiomyopathy; amyloid deposits between myofibers
  • "Sparkling" appearance on echocardiogram

Staining and Diagnosis

  1. Congo red stain - salmon-pink color on routine light microscopy; apple-green birefringence under polarized light (PATHOGNOMONIC)
  2. Electron microscopy - non-branching fibrils, 7.5-10 nm in diameter
  3. Crystal violet - metachromasia (amyloid stains red/violet against blue background)
  4. Thioflavin T or S - fluorescence under UV light

Clinical Features

  • Renal: Nephrotic syndrome, progressive renal failure
  • Cardiac: Restrictive cardiomyopathy, arrhythmias, heart block
  • Hepatic: Hepatomegaly, elevated ALP, rarely liver failure
  • Neurologic: Peripheral neuropathy, autonomic neuropathy, carpal tunnel syndrome
  • GI: Malabsorption, dysmotility
  • Macroglossia (enlarged tongue) - classic sign of AL amyloidosis

All answers based on Robbins, Cotran & Kumar Pathologic Basis of Disease and Goldman-Cecil Medicine.
attachment
attachment
attachment
attachment
attachment
attachment

Do same for these make flowchart where ever necessary

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File

Pathology Paper I - Complete Exam Answers (Pages 4-7)


IMMUNOPATHOLOGY (Continued from Page 4)


LAQ 1. Autoimmunity - Definition and Pathogenesis

Definition

Autoimmunity is a condition in which the immune system mounts a sustained, self-damaging immune response against the body's own (self) tissues and antigens, due to a failure of self-tolerance. Normally, self-reactive lymphocytes are eliminated or suppressed; when these mechanisms break down, autoimmunity results.

Self-Tolerance - Normal Mechanisms

Central tolerance:
  • In the thymus (T cells) and bone marrow (B cells), lymphocytes that recognize self-antigens with high affinity are deleted by clonal deletion (apoptosis)
  • Remaining weakly self-reactive T cells in the thymus may be diverted to become Tregs (regulatory T cells)
Peripheral tolerance:
  • Clonal anergy: Self-reactive T cells that escape the thymus encounter self-antigen without co-stimulation → become anergic (unresponsive)
  • Regulatory T cells (Tregs): CD4+CD25+FoxP3+ Tregs suppress self-reactive effectors via IL-10, TGF-β
  • Clonal deletion: Peripheral apoptosis of self-reactive cells

Pathogenesis of Autoimmunity (Flowchart)

GENETIC SUSCEPTIBILITY (HLA genes, non-HLA genes)
           +
ENVIRONMENTAL TRIGGERS (infections, drugs, UV radiation, tissue injury)
           ↓
FAILURE OF SELF-TOLERANCE
           ↓
    ┌──────────────────────────────────────────────┐
    │                                              │
CENTRAL TOLERANCE FAILURE          PERIPHERAL TOLERANCE FAILURE
(clonal deletion incomplete)       (anergy failure, Treg deficiency)
    │                                              │
    └─────────────────┬────────────────────────────┘
                      ↓
    ACTIVATION OF SELF-REACTIVE LYMPHOCYTES
                      ↓
    ┌─────────────────┴──────────────────┐
    │                                    │
Self-reactive CD4+ T cells          Self-reactive B cells
    │                                    │
    ↓                                    ↓
Cytokine release → inflammation    Autoantibodies (IgG, IgM)
    │                                    │
    └─────────────────┬──────────────────┘
                      ↓
            TISSUE DAMAGE (autoimmune disease)

Mechanisms of Autoimmunity

1. Failure of Clonal Deletion / Central Tolerance:
  • Mutations in AIRE gene (autoimmune regulator) in thymic medullary epithelial cells → failure to present peripheral self-antigens to developing T cells → self-reactive T cells escape deletion
  • AIRE mutations → APS-1 (Autoimmune Polyglandular Syndrome type 1)
2. Failure of Peripheral Tolerance:
  • Loss of anergy: If self-antigens are presented with co-stimulatory signals (e.g., during inflammation), anergic self-reactive cells get reactivated
  • Treg deficiency/dysfunction: Mutation in FoxP3 gene → IPEX syndrome (immune dysregulation, polyendocrinopathy, enteropathy, X-linked)
  • Failure of activation-induced cell death (AICD): Defects in Fas-FasL pathway → lymphoproliferative disease (ALPS)
3. Molecular Mimicry:
  • Microbial antigens share structural similarity with self-antigens
  • Antibodies or T cells generated against the microbe cross-react with self-tissue
  • Example: Group A Streptococcus M protein → cross-reacts with cardiac myosin → Rheumatic fever
4. Bystander Activation:
  • Infections cause local inflammation, danger signals (DAMPs), and upregulation of MHC molecules and co-stimulators on APCs
  • Self-reactive T cells that had been previously anergic are now activated by the inflammatory milieu without specific antigen recognition
5. Abnormal Display of Self-Antigens (Epitope spreading):
  • Tissue injury exposes cryptic self-antigens (normally sequestered, e.g., intracellular proteins)
  • These "neoantigens" were never tolerized during thymic development
  • Post-translational modifications (citrullination) can alter self-peptides → new epitopes
  • Example: Citrullinated peptides in rheumatoid arthritis → anti-CCP antibodies
6. Genetic Factors:
  • HLA associations (strongest genetic risk factor):
    • HLA-DR4 → RA
    • HLA-DR3/DR4 → Type 1 Diabetes
    • HLA-DR2 → SLE, Goodpasture
    • HLA-B27 → Ankylosing spondylitis (100-200x risk)
  • Non-HLA genes: PTPN22 (T cell signaling), CTLA4, IL-2RA

LAQ 2. AIDS - Etiology, Routes of Transmission, Natural History (Phases), Diagnosis

Definition

AIDS (Acquired Immunodeficiency Syndrome) is the advanced stage of infection with Human Immunodeficiency Virus (HIV), characterized by severe immunodeficiency resulting in opportunistic infections, certain malignancies, and neurological disease.

Etiology

  • Causative agent: HIV-1 (most common worldwide) and HIV-2 (West Africa, less virulent)
  • Classification: Retrovirus, family Retroviridae, subfamily Lentivirinae
  • Structure:
    • Outer lipid envelope with gp120 (binds CD4 and co-receptor) and gp41 (mediates membrane fusion)
    • Core: contains 2 copies of single-stranded RNA genome + reverse transcriptase, integrase, protease
    • Genome: gag (core proteins), pol (enzymes), env (envelope glycoproteins) + regulatory genes (tat, rev, nef, vif, vpr, vpu)
Mechanism of CD4+ T cell infection:
  1. gp120 binds CD4 receptor on T helper cells, macrophages, dendritic cells
  2. Conformational change → gp120 binds co-receptor (CCR5 on macrophages - early infection; CXCR4 on T cells - late infection)
  3. gp41 mediates membrane fusion
  4. Viral core enters cell → reverse transcriptase converts RNA → double-stranded DNA
  5. Viral DNA integrates into host genome as provirus
  6. Viral replication → new virions bud off → CD4+ T cell death

Routes of Transmission

  1. Sexual transmission (most common globally):
    • Unprotected heterosexual intercourse (main route in Africa/Asia)
    • MSM (men who have sex with men) - highest risk per exposure
    • Receptive anal intercourse carries highest risk
  2. Parenteral (blood-borne):
    • Intravenous drug users sharing needles
    • Blood transfusions and blood products (before screening was implemented)
    • Accidental needlestick injuries (healthcare workers - ~0.3% risk per exposure)
  3. Mother-to-child (vertical) transmission:
    • In utero (transplacental, 20-30%)
    • During delivery (most common)
    • Via breastfeeding (post-natal, 10-15%)
NOT transmitted by: casual contact, saliva, tears, sweat, mosquitoes, toilet seats

Natural History / Phases of HIV Infection (Flowchart)

HIV EXPOSURE & INFECTION
         ↓
[PHASE 1] ACUTE HIV SYNDROME (2-4 weeks after exposure)
• "Mononucleosis-like" illness
• Fever, malaise, lymphadenopathy, rash, myalgia
• High viral load (viremia) → virus spreads to lymphoid tissue
• CD4+ count drops transiently
• Seroconversion occurs (anti-HIV antibodies appear)
• Self-limiting (resolves in weeks)
         ↓
[PHASE 2] CLINICAL LATENCY / CHRONIC ASYMPTOMATIC INFECTION
• Duration: 2-10 years (average ~7-10 years without treatment)
• Patient feels well; may have persistent generalized lymphadenopathy (PGL)
• CD4+ count slowly declines (normal 500-1500/μL; declines ~50 cells/year)
• Continuous HIV replication in lymph nodes; viral load ~10,000-100,000 copies/mL
• At CD4 <500: minor opportunistic infections begin
         ↓
[PHASE 3] AIDS (CD4+ <200 cells/μL OR AIDS-defining illness)
• Constitutional symptoms: fever, night sweats, weight loss (>10% body weight)
• Severe opportunistic infections (see below)
• AIDS-defining malignancies
• Neurological disease
• Without treatment: death within 2-3 years
AIDS-defining Opportunistic Infections (CD4 count at which they occur):
CD4 CountOpportunistic Infection
<500Herpes zoster, oral thrush (Candida), TB
<200PCP (Pneumocystis jirovecii pneumonia), Toxoplasma encephalitis
<100Cryptosporidium, Cryptococcal meningitis, CMV retinitis
<50MAC (Mycobacterium avium complex), CMV colitis
AIDS-defining Malignancies:
  • Kaposi sarcoma (HHV-8; purplish skin/oral lesions)
  • Non-Hodgkin lymphoma (especially CNS lymphoma)
  • Invasive cervical carcinoma (HPV-related)

Diagnosis

1. Screening tests:
  • ELISA (4th generation): Detects both p24 antigen AND anti-HIV antibodies; window period ~18-45 days; high sensitivity (~99.9%)
  • Rapid HIV antibody tests (point-of-care)
2. Confirmatory tests:
  • Western Blot: Detects antibodies to specific HIV proteins (gp120, gp41, p24); positive if bands for ≥2 of: gp24, gp41, gp120/160
  • HIV RNA PCR (viral load): Detects HIV RNA directly; used for diagnosis in early infection (before seroconversion), newborns (maternal antibodies confound serology), and for monitoring treatment response
3. Monitoring tests:
  • CD4+ T cell count - monitors immune status; <200/μL = AIDS
  • HIV RNA viral load - monitors response to antiretroviral therapy (ART); goal is undetectable (<50 copies/mL)
  • CBC, chemistry panel - baseline and monitoring for ART toxicity
  • Resistance genotyping - before starting ART


SECTION: Derangements of Homeostasis and Haemodynamics


SN 1. Infarct - Definition and Types

Definition

An infarct is an area of ischemic necrosis caused by occlusion of either the arterial supply or the venous drainage of the affected tissue. It is the most common cause of serious illness and death in developed countries.

Types of Infarcts

Based on COLOR:
FeatureRed (Hemorrhagic) InfarctWhite (Anemic/Pale) Infarct
ColorRed due to blood extravasationPale/white due to lack of blood
Tissue typeLoose/spongy texture (lung); dual circulation (lung, small intestine)Solid organs with end-arteries
MechanismVenous occlusion; dual blood supply; reperfusionArterial occlusion in solid organs
ExamplesLung infarct, bowel infarct, testicular torsionRenal infarct, splenic infarct, cardiac infarct
ShapeIrregularWedge-shaped (base toward surface, apex toward hilum)
Based on INFECTION:
  • Bland (aseptic) infarct - no bacterial infection (most infarcts)
  • Septic infarct - bacterial emboli seed the infarct; can form abscesses; e.g., infective endocarditis
Based on MECHANISM:
  • Arterial infarct - most common; arterial thrombosis or embolism
  • Venous infarct - venous occlusion; uncommon; more likely in organs with single efferent vein (testis, ovary)
Factors affecting outcome:
  1. Adequacy of collateral circulation (e.g., dual supply of lung)
  2. Rate of development of occlusion (gradual = collaterals develop)
  3. Tissue vulnerability to ischemia: neurons (4-5 min) > myocardium (20-30 min) > fibroblasts (hours)
  4. Oxygen content of blood (anaemia worsens outcome)

SN 2. Gross and Microscopic Features of Liver and Spleen in Right-Sided Heart Failure

Right-Sided Heart Failure (RHF)

In RHF, there is increased central venous pressure (CVP) with passive congestion of all organs that drain into the systemic venous circulation, particularly the liver and spleen.

LIVER (Nutmeg Liver / Chronic Passive Congestion)

Pathophysiology:
  • Elevated CVP → hepatic veins dilate → centrilobular sinusoids become engorged with blood → centrilobular hepatocyte necrosis (zone 3 = most vulnerable, least oxygen) → fibrosis over time (cardiac cirrhosis)
Gross Features:
  • Liver is enlarged (hepatomegaly), heavy, firm, tense
  • Cut surface shows a characteristic "nutmeg" pattern: alternating dark red (congested centrilobular areas) and yellow-tan (fatty change in periportal hepatocytes) areas - resembles the cut surface of a nutmeg
  • In chronic cases: cardiac cirrhosis - fine fibrous strands radiating from central veins (reversed lobulation pattern)
Microscopic Features:
  • Centrilobular (zone 3) sinusoidal dilation - sinusoids engorged with red blood cells
  • Centrilobular hepatocyte necrosis - hepatocytes in zone 3 show cell death
  • Fatty change (steatosis) in periportal (zone 1) hepatocytes - contrast creates the nutmeg appearance
  • In chronic/severe cases: centrilobular fibrosis → bridges between central veins (cardiac cirrhosis / "reversed lobulation")
  • Over time: atrophy and loss of hepatocytes in centrilobular zones

SPLEEN (Congestive Splenomegaly)

Gross Features:
  • Enlarged (splenomegaly) - may reach 250-300g (normal ~150g)
  • Capsule is tense and smooth
  • Cut surface: dark red/bluish-red, firm, congested
Microscopic Features:
  • Dilated, engorged sinusoids in red pulp
  • Fibrosis of sinusoidal walls (Gamna-Gandy bodies - hemosiderin-laden macrophages with calcium deposits)
  • Red pulp is expanded; white pulp is compressed and atrophied
  • Occasional foci of old hemorrhage with hemosiderin deposition
  • In chronic cases: thickening of sinusoidal walls (fibrocongestive splenomegaly)

SN 3. Virchow's Triad - Role in Thrombus Formation

Virchow's Triad

Rudolf Virchow (1856) described three major factors predisposing to thrombosis - collectively known as Virchow's Triad:
┌─────────────────────────────────────────┐
│         VIRCHOW'S TRIAD                 │
│                                         │
│    ENDOTHELIAL INJURY                   │
│           ↕ (most important)            │
│    ABNORMAL BLOOD FLOW ←→ HYPERCOAGULABILITY│
│    (stasis or turbulence)               │
└─────────────────────────────────────────┘
These three may promote thrombosis independently or together
1. Endothelial Injury (most important factor for arterial thrombosis):
  • Normal endothelium is anti-thrombotic: produces prostacyclin (PGI2), NO, thrombomodulin, heparin-like molecules, t-PA
  • Injured/activated endothelium becomes PRO-thrombotic:
    • Downregulates thrombomodulin, protein C, t-PA
    • Exposes subendothelial collagen and von Willebrand factor (vWF) → platelet adhesion
    • Synthesizes tissue factor → activates extrinsic coagulation cascade
    • Releases PAI-1 (inhibits fibrinolysis)
  • Causes: atherosclerosis, hypertension, hypercholesterolaemia, bacterial toxins, radiation, smoking
2. Abnormal Blood Flow (Stasis and Turbulence):
  • Stasis: Slow-moving blood allows accumulation of activated clotting factors; prevents their dilution; prevents mixing with natural anticoagulants; allows platelets to contact endothelium
    • Causes of stasis: atrial fibrillation, dilated cardiomyopathy, deep vein thrombosis in immobilized patients, varicose veins
  • Turbulence: Disrupts laminar flow; causes endothelial injury; creates downstream eddies that promote platelet contact with vessel wall
    • Causes of turbulence: atherosclerotic plaques, vessel bifurcations, aneurysms, prosthetic heart valves
3. Hypercoagulability:
  • Primary (hereditary): Factor V Leiden mutation (most common - activated protein C resistance), Prothrombin gene G20210A mutation, Antithrombin III deficiency, Protein C or S deficiency
  • Secondary (acquired): Prolonged bed rest, cancer (Trousseau syndrome - migratory thrombophlebitis), pregnancy, oral contraceptives, antiphospholipid antibody syndrome (lupus anticoagulant), HIT (heparin-induced thrombocytopenia)

SN 4. Air Embolism

Definition

Air (or gas) embolism occurs when air or other gas enters the vascular system in sufficient quantity to cause mechanical obstruction of blood flow.

Causes

  1. Trauma to large veins (neck veins, subclavian veins): penetrating injuries; central venous catheter insertion/removal (especially if patient is upright and inspires)
  2. Obstetric procedures: during delivery, abortion, or insufflation procedures (uterine veins torn; air sucked in by negative uterine pressure) 3.Decompression sickness (Caisson disease): Rapid ascent from high-pressure environments (deep-sea diving). Nitrogen dissolved under high pressure forms bubbles in blood and tissues as pressure rapidly drops.
  3. Laparoscopic surgery: CO2 insufflation may accidentally enter a vessel
  4. Cardiopulmonary bypass and open-heart surgery

Pathogenesis and Effects

Volume required: Approximately 100-150 mL of air is required to produce significant systemic effects. Small amounts (<10 mL) are usually absorbed harmlessly.
Venous air embolism:
  • Air enters a vein → travels to right heart → frothy air/blood mixture → right ventricular outflow obstruction
  • Frothy blood cannot be pumped efficiently by the right ventricle → acute right heart failure
  • Large air emboli can occlude the pulmonary outflow tract → sudden death ("air-lock")
Arterial air embolism:
  • Air enters arterial system (through pulmonary AVMs, cardiac defects, or iatrogenic) → coronary arteries → MI; cerebral arteries → stroke
Decompression sickness specifically:
  • Gas emboli in joints → joint pain ("the bends")
  • Pulmonary emboli → "the chokes" (dyspnoea, coughing)
  • Cerebral emboli → neurological symptoms ("the staggers")
  • Chronic form: caisson disease - aseptic bone necrosis (femoral head most common) due to ischemic necrosis from persistent nitrogen bubbles in bone
Treatment: Hyperbaric oxygen (recompression) therapy

SN 5. Pulmonary Thromboembolism

Definition

Pulmonary embolism (PE) is the lodgement of a thrombus (or other material) in the pulmonary arterial tree. >95% of PE arise from deep vein thrombosis (DVT) of the lower extremities (popliteal, femoral, iliac veins).

Pathogenesis

DVT (deep veins of leg/pelvis)
         ↓
Thrombus detaches (embolus)
         ↓
Travels through IVC → right atrium → right ventricle
         ↓
Enters pulmonary arterial circulation
         ↓
Lodges in pulmonary artery or branch
         ↓
Depends on SIZE:
    ├─ MASSIVE (>60% pulmonary circulation occluded)
    │       → Acute cor pulmonale → sudden death
    ├─ MAJOR/SUBMASSIVE (medium-sized arteries)
    │       → Pulmonary infarction (red hemorrhagic infarct)
    │       → Pleuritic chest pain, haemoptysis, dyspnoea
    └─ MINOR/SMALL (arterioles, small branches)
            → Often asymptomatic
            → Multiple episodes → pulmonary hypertension

Morphological Appearances

Gross: Classic pulmonary infarct is:
  • Wedge-shaped, with base toward the pleural surface and apex pointing toward the hilum
  • Red/hemorrhagic (hemorrhagic infarct) - because the lung has dual circulation
  • Located in lower lobes (preferential blood flow)
  • Well-demarcated, hemorrhagic, firm
  • Overlying pleura shows fibrinous pleuritis
Microscopic:
  • Alveolar walls filled with red blood cells (hemorrhagic necrosis)
  • Necrosis of alveolar septa
  • Over time: organization with fibrous scar formation

Clinical Features

TypeFeatures
Massive PESudden onset dyspnoea, hypotension, shock, cyanosis, syncope, death
Major PEPleuritic chest pain, haemoptysis, dyspnoea, friction rub, pleural effusion
Small/Multiple PEDyspnoea on exertion, pulmonary hypertension, right heart failure
ECG classic pattern: S1Q3T3 (S wave in lead I, Q wave + inverted T in lead III); right heart strain; sinus tachycardia
Diagnosis: CT pulmonary angiography (CTPA) - gold standard; V/Q scan; D-dimer; echocardiography

LAQ 1. Oedema - Definition, Types, Pathogenesis, Pulmonary Oedema, Transudate vs Exudate

Definition

Oedema is the accumulation of interstitial fluid in excess of normal in tissues or body cavities. Accumulation in body cavities:
  • Hydrothorax (pleural cavity)
  • Hydropericardium (pericardial cavity)
  • Hydroperitoneum/Ascites (peritoneal cavity)
  • Anasarca = generalized, massive oedema of the whole body

Pathogenesis - Starling Forces (Flowchart)

NORMAL FLUID BALANCE:
Capillary hydrostatic pressure pushes fluid OUT
Plasma oncotic (colloid osmotic) pressure holds fluid IN
Net filtration = Net reabsorption (lymphatics drain excess)

OEDEMA WHEN:
┌──────────────────────────────────────────────────┐
│1. ↑ Hydrostatic pressure → excess filtration out │
│   (Heart failure, venous obstruction, cirrhosis) │
├──────────────────────────────────────────────────┤
│2. ↓ Plasma oncotic pressure → less reabsorption  │
│   (Hypoalbuminaemia: nephrotic, malnutrition, CLD)│
├──────────────────────────────────────────────────┤
│3. ↑ Vascular permeability → protein leaks out    │
│   (Inflammation, burns, allergy, sepsis)         │
├──────────────────────────────────────────────────┤
│4. Lymphatic obstruction → fluid not drained       │
│   (Filariasis, tumour, post-mastectomy lymphoedema)│
├──────────────────────────────────────────────────┤
│5. Sodium and water retention                      │
│   (Renal failure, CHF → RAAS activation)         │
└──────────────────────────────────────────────────┘

Types of Oedema

TypeMechanismExamples
Cardiac oedema↑ venous hydrostatic pressure + Na+ retentionCHF: bilateral dependent, pitting oedema; ascites
Renal oedema↓ oncotic pressure (proteinuria) + Na+ retentionNephrotic syndrome: periorbital oedema first, then generalised
Hepatic oedema↓ albumin synthesis + portal hypertensionCirrhosis: ascites predominantly
Inflammatory oedema↑ vascular permeability (exudate)Infections, allergy, burns
LymphoedemaLymphatic obstructionFilariasis (elephantiasis), post-mastectomy
Nutritional↓ oncotic pressure (hypoalbuminaemia)Kwashiorkor, starvation

Pulmonary Oedema (Primary Left Heart Failure - LAQ sub-question)

Pathophysiology:
Left ventricular failure
         ↓
↑ Left ventricular end-diastolic pressure (LVEDP)
         ↓
↑ Left atrial pressure
         ↓
↑ Pulmonary venous pressure
         ↓
↑ Pulmonary capillary hydrostatic pressure
(exceeds oncotic pressure of ~25 mmHg)
         ↓
Fluid leaks from pulmonary capillaries into:
    1. Perivascular and peribronchial space (first)
    2. Interstitial space (alveolar walls thicken)
    3. Alveolar space (frothy pink sputum)
         ↓
Impaired gas exchange → hypoxia → dyspnoea
Gross Features:
  • Lungs are heavy, wet (2-3x normal weight; normal ~400g per lung)
  • Cut surface oozes frothy, blood-tinged fluid (mixture of air + oedema fluid + extravasated RBCs)
  • Congested, deep red/dark colour
Microscopic Features:
  • Dilated and engorged capillaries in alveolar walls (hyperaemia)
  • Alveolar septa thickened by oedema fluid
  • Alveolar spaces filled with:
    • Proteinaceous eosinophilic fluid
    • Red blood cells (diapedesis)
    • Macrophages with engulfed haemosiderin = "heart failure cells" (siderophages - brown granular cytoplasm, positive with Prussian blue stain)
  • In chronic cases: haemosiderosis (widespread haemosiderin deposition)

Transudate vs Exudate

FeatureTransudateExudate
Protein contentLow (<3 g/dL)High (>3 g/dL)
Specific gravity<1.012>1.020
CellsFew (mainly mesothelial)Many (neutrophils, macrophages)
LDHLowHigh
AppearanceClear, straw-coloured, wateryCloudy, turbid, may be purulent
Light's criteriaDoes not meet criteriaMeets ≥1 Light criterion
Fibrin/ClotDoes not clotMay clot (fibrinogen present)
MechanismIncreased hydrostatic pressure or decreased oncotic pressure; intact capillary wallIncreased vascular permeability; protein leaks through damaged capillary wall
CausesCHF, nephrotic syndrome, cirrhosis, hypoalbuminaemiaInfections, malignancy, pancreatitis, TB, rheumatoid pleuritis
Light's Criteria (exudate if any ONE present):
  1. Pleural protein/serum protein >0.5
  2. Pleural LDH/serum LDH >0.6
  3. Pleural LDH >2/3 upper limit of normal serum LDH

LAQ 2. Embolism - Definition, Types, Pathogenesis, Morphology, Fate

Definition

An embolus is a detached intravascular solid, liquid, or gaseous mass that is carried by the blood to a site distant from its point of origin. The process of lodgement is called embolism. The vast majority of emboli are dislodged thrombi (thromboembolism).

Types of Emboli

TypeSourceDestination
ThromboembolismDVT of leg veins (most common)Pulmonary arteries
Fat embolismBone marrow fat; traumatic adiposeLung, brain, kidney
Air embolismVeins (during surgery, trauma, decompression)Right heart, lung
Amniotic fluid embolismUterine veins during deliveryLung (fatal)
Tumour embolismMalignant cellsAny organ (basis of haematogenous metastasis)
Cholesterol embolismAtheromatous plaque ruptureLower extremity arteries, kidneys
Septic embolismInfected thrombus (IE, sepsis)Any organ
Paradoxical embolismVenous thrombus crosses ASD/VSD/PFO → arterial circulationBrain, kidneys, extremities

Fat Embolism Syndrome

Sources:
  • Fractures of long bones (femur, tibia) - bone marrow fat released
  • Severe soft tissue trauma (crush injuries)
  • Orthopaedic procedures
Pathogenesis:
Bone/soft tissue injury
         ↓
Fat globules enter disrupted venous sinusoids/vessels
         ↓
Travel to pulmonary microcirculation
         ↓
Physical obstruction of capillaries
+
Hydrolysis of neutral fat → free fatty acids (toxic to endothelium)
         ↓
Pulmonary oedema, haemorrhage, ARDS
         ↓
Fat crosses through pulmonary AV anastomoses OR through patent foramen ovale
         ↓
Systemic (cerebral, renal) fat emboli
Classic clinical triad (appears 24-72 hours after injury):
  1. Respiratory failure (dyspnoea, hypoxia)
  2. Neurological features (confusion, restlessness, coma)
  3. Petechial rash (on chest, axillae, conjunctivae) - pathognomonic

Fate of Emboli (Pulmonary Thromboemboli specifically)

PULMONARY EMBOLUS
         ↓
    ┌────┴────────────────────────────────────────┐
    │                                             │
IMMEDIATE DEATH             LODGES IN PULMONARY ARTERY
(massive saddle embolus)            ↓
                         ┌──────────┴───────────────┐
                         │                          │
               FIBRINOLYSIS                  ORGANIZATION &
               (clot dissolves,              INCORPORATION
               vessel reopens)               into vessel wall
                         ↓                  (eventual recanalisation)
                  Complete recovery
                                    ┌────────────────────┐
                                    │ IF INFARCTION occurs│
                                    │ (depends on adequacy│
                                    │ of collateral circ) │
                                    ↓                    │
                              Red wedge-shaped           │
                              haemorrhagic infarct        │
                                    ↓                    │
                              Fibrous scar (white)        │
                                    └────────────────────┘
           MULTIPLE SMALL EMBOLI OVER TIME
                         ↓
               Pulmonary hypertension
                         ↓
               Right heart failure (cor pulmonale)

LAQ 3. Thrombus - Definition, Pathogenesis, Types, Fate, Complications

Definition

A thrombus is a solid mass formed from the constituents of blood (platelets, fibrin, RBCs, WBCs) within the living vascular system during life, in response to injury or stasis. It differs from a post-mortem clot (which is gelatinous, lacks lines of Zahn, and does not adhere to vessel wall).

Pathogenesis (Virchow's Triad - detailed above)

Steps in thrombus formation:
ENDOTHELIAL INJURY / STASIS / HYPERCOAGULABILITY
         ↓
Platelet adhesion to exposed collagen (via vWF)
         ↓
Platelet activation → shape change → granule release
(ADP, TXA2 = amplify platelet activation)
         ↓
Platelet aggregation (platelet plug formation)
         ↓
Coagulation cascade activation
(Tissue factor → extrinsic pathway;
 exposed collagen activates factor XII → intrinsic pathway)
         ↓
Thrombin generated → fibrinogen → FIBRIN
         ↓
Fibrin mesh entraps platelets, RBCs, WBCs
         ↓
THROMBUS formed

Lines of Zahn

Gross laminated appearance in arterial thrombi: alternating pale layers (platelet/fibrin-rich) and red layers (RBC-rich), laid down as the clot builds. Confirm that a thrombus formed during life (absent in post-mortem clots).

Types of Thrombi

FeatureArterial ThrombusVenous ThrombusCardiac Mural Thrombus
ColourWhite/pale (platelet-rich)Red (RBC-rich)Mixed
StructureLines of Zahn visibleHomogeneous red clotLines of Zahn if in ventricle
CauseAtherosclerosis, turbulenceStasis, hypercoagulabilityMI, AF, cardiomyopathy
AttachmentFirmly attached to wallMay be free at one endAttached to myocardium/valve
TendencyEmbolise to brain, kidneyEmbolise to lungsEmbolise systemically or to lungs
LocationCoronary, cerebral, femoral arteriesDeep leg veins, pelvic veinsLeft ventricle, atria

Fate of Thrombus (4R + 2C)

THROMBUS
    ├─→ 1. RESOLUTION (fibrinolysis)
    │       Small, fresh thrombus dissolved by plasminogen/t-PA system
    │       → Complete vascular recanalization
    │
    ├─→ 2. ORGANISATION & RECANALISATION
    │       Thrombus invaded by fibroblasts, smooth muscle cells, endothelial cells
    │       → Fibrosed thrombus incorporated into vessel wall
    │       → New capillary channels form through it (recanalisation)
    │
    ├─→ 3. PROPAGATION
    │       Thrombus enlarges (adds more clot) → greater risk of embolism
    │
    ├─→ 4. CALCIFICATION
    │       Old organized thrombi may calcify
    │       → "Phleboliths" in veins; calcified plaques in arteries
    │
    ├─→ 5. EMBOLISATION (complication)
    │       Thrombus fragments detach → travel to distant sites
    │
    └─→ 6. INFECTION (complication)
            Bacteria seed the thrombus → mycotic aneurysm, septic emboli

Complications of Thrombosis

  1. Embolism - most serious; DVT → pulmonary embolism; cardiac mural thrombus → stroke, renal infarct
  2. Infarction - downstream ischemic necrosis (MI, stroke)
  3. Venous congestion - DVT causing oedema, pain, skin ulceration
  4. Post-thrombotic syndrome - chronic venous insufficiency after DVT
  5. DIC (disseminated intravascular coagulation) - widespread microvascular thrombosis → consumption of clotting factors → bleeding
  6. Paradoxical embolism - VTE crossing to arterial side via PFO


SECTION: Inflammation and Healing


SN 1. Chemotaxis and Phagocytosis

Chemotaxis

Definition: Chemotaxis is the directed migration of leukocytes (especially neutrophils) along a chemical gradient toward the site of injury/infection.
Chemoattractants (chemotaxins):
  • Bacterial products: N-formyl-methionyl peptides (fMLP) - the most potent chemotaxin
  • Complement components: C5a (most important endogenous chemotaxin)
  • Arachidonic acid metabolites: Leukotriene B4 (LTB4)
  • Cytokines: IL-8 (CXCL8), MCP-1 (for monocytes)
Mechanism:
  1. Chemotaxin binds to G-protein-coupled receptor on neutrophil
  2. Activates PLC → IP3 (Ca2+ release) + DAG (PKC activation)
  3. Cytoskeletal reorganisation: F-actin polymerises at leading edge (lamellipodia form)
  4. Cell polarises and migrates toward the gradient

Phagocytosis

Definition: The process by which phagocytes (neutrophils and macrophages) engulf and destroy foreign particles, microbes, and debris.
Steps (Flowchart):
RECOGNITION AND ATTACHMENT
(Opsonization enhances this step)
Opsonins: IgG (Fc receptor), C3b (CR1 receptor), MBL
         ↓
ENGULFMENT
Phagocyte extends pseudopods around the particle
Pseudopods fuse → PHAGOSOME forms
         ↓
FUSION WITH LYSOSOMES
Phagosome + lysosome → PHAGOLYSOSOME
         ↓
KILLING AND DEGRADATION
    ├─ OXYGEN-DEPENDENT (most important)
    │   ├─ NADPH oxidase → superoxide (O2•-) → H2O2 → HOCl (hypochlorite) - MPO system
    │   └─ Myeloperoxidase (MPO) + H2O2 + Cl- → hypochlorite (HOCL) - most potent bactericide
    │
    └─ OXYGEN-INDEPENDENT
        ├─ Lysozyme (attacks bacterial cell wall)
        ├─ Lactoferrin (chelates iron)
        ├─ Defensins (membrane-disruptive peptides)
        ├─ Major basic protein (eosinophils - parasites)
        └─ Cathepsin G, elastase (proteolytic)
         ↓
DEAD MICROBE DEGRADED BY LYSOSOMAL ENZYMES
(proteases, lipases, nucleases)

SN 2. Common Sites of Primary Tuberculosis and Pathogenesis of TB

Primary Tuberculosis

Most common site: The lower part of the upper lobe and upper part of the lower lobe of the lung (well-ventilated areas with high oxygen tension where M. tuberculosis thrives). Specifically, the subpleural location in the middle zones.
Other sites of primary TB:
  • Intestine (especially ileocaecal region) - ingested bovine TB
  • Tonsillar/pharyngeal - via ingestion or inhalation
  • Skin (primary cutaneous TB) - rare

Pathogenesis of TB (Flowchart)

INHALATION of M. tuberculosis (droplet nuclei, <5 μm)
         ↓
Bacteria reach alveoli
         ↓
Phagocytosed by ALVEOLAR MACROPHAGES
(but TB survives by inhibiting phagolysosome fusion)
         ↓
Bacteria replicate within macrophages → spread to
regional lymph nodes (hilar nodes)
         ↓
GHON FOCUS forms (subpleural lung lesion)
+ hilar lymph node involvement
= GHON COMPLEX (PRIMARY COMPLEX)
         ↓
    ┌────┴────────────────────────┐
    │                             │
T-cell-mediated immunity       Bacteria persist
develops after 4-8 weeks       in granulomas
    │
    ↓
CELL-MEDIATED IMMUNE RESPONSE
(Th1 cells, CD4+, IFN-γ)
    │
    ↓
Macrophage activation by IFN-γ
    │
    ↓
GRANULOMA FORMATION
(Epithelioid macrophages + Langhans giant cells + lymphocytes)
    │
    ↓
Central CASEOUS NECROSIS
    │
    ↓
    ├─ HEALING: calcification, fibrosis (most patients)
    │
    └─ PROGRESSION (if immunity fails):
         ↓
    SECONDARY/POST-PRIMARY TB
    (reactivation or reinfection)
    ↓
Cavitation, haematogenous spread, miliary TB

SN 3 & 4. Morphological Features of Pulmonary Tuberculosis and Ghon's Complex

Ghon's Complex (Primary Complex)

Components:
  1. Ghon focus (Ghon lesion): Subpleural area of pneumonia (consolidation) in the lower lobe or upper lobe (mid-zone), 1-1.5 cm. Initially shows non-specific exudative inflammation, then develops into a caseating granuloma.
  2. Lymphangitis: Lymphatic spread from the Ghon focus toward the hilum
  3. Hilar/mediastinal lymph node enlargement: Caseating granulomas in the draining lymph nodes
Together: Ghon focus + lymphangitis + hilar node = Ranke complex (fully developed primary complex)
Gross Appearance of Ghon Focus:
  • Small (1-1.5 cm), firm, yellowish-white, subpleural lesion
  • Cheese-like (caseous) centre
  • Surrounding fibrous capsule
Microscopic Appearance:
  • Central caseous necrosis (acellular, eosinophilic, granular debris)
  • Surrounding rim of epithelioid macrophages (activated macrophages with pale eosinophilic cytoplasm and vesicular nuclei)
  • Langhans giant cells (nuclei arranged in horseshoe/peripheral pattern)
  • Peripheral lymphocytes and plasma cells
  • ± fibrosis and calcification
Fate of Ghon Complex:
GHON COMPLEX
    ├─ HEALING (majority - immunity intact):
    │   Caseous necrosis → inspissation → CALCIFICATION (dystrophic)
    │   → Fibrosis and dense fibrous scar
    │   Calcified Ghon complex on CXR = "Ranke complex"
    │
    ├─ PROGRESSIVE PRIMARY TB (young children, immunocompromised):
    │   Ghon focus enlarges → lobar pneumonia
    │   Hilar node softens → erodes into bronchus → endobronchial TB
    │   Haematogenous spread → Miliary TB
    │
    └─ LATENT INFECTION:
        Bacteria remain dormant in calcified foci
        Reactivation years later = Post-primary/Secondary TB

Morphological Features of Pulmonary Tuberculosis (Post-primary/Secondary TB)

Gross: Affects upper lobes (apices) preferentially. Shows:
  • Consolidation (exudative) with caseous centre
  • Cavitation - caseous material liquefied and drains into bronchus → cavity (hallmark of secondary TB); cavity wall lined by caseous material
  • Fibrocaseous lesions - older lesions with fibrosis + caseous centres
  • Satellite lesions around main foci
Microscopic: Same granulomatous structure with central caseous necrosis, epithelioid macrophages, Langhans giant cells, lymphocytes. In cavities: the cavity wall shows granulation tissue and fibrous tissue around caseous necrosis.

LAQ 1. Inflammation - Cardinal Signs, Acute Inflammation (Vascular + Cellular + Chemical Mediators), Acute vs Chronic

Definition of Inflammation

Inflammation is a vascular and cellular response of living tissues to injury, infection, or irritation aimed at eliminating the causative agent, removing dead tissue, and initiating repair.
Cardinal signs (Celsus + Virchow = 5):
  1. Rubor (Redness) - vasodilation
  2. Calor (Heat) - increased blood flow
  3. Tumor (Swelling) - increased vascular permeability + exudate
  4. Dolor (Pain) - prostaglandins, bradykinin stimulate nociceptors
  5. Functio laesa (Loss of function) - added by Virchow

Acute Inflammation - VASCULAR EVENTS

INJURY
    ↓
TRANSIENT VASOCONSTRICTION (seconds)
    ↓
VASODILATION (arterioles first, then capillaries)
- Mediators: HISTAMINE (immediate), NITRIC OXIDE (sustained)
- Result: increased blood flow → heat and redness
    ↓
INCREASED VASCULAR PERMEABILITY
- Endothelial cells contract → intercellular gaps form
- Mediators: Histamine, serotonin, C3a/C5a (anaphylatoxins), bradykinin, leukotrienes
- Protein-rich fluid (exudate) leaks into interstitium → OEDEMA
    ↓
STASIS OF BLOOD FLOW
- Increased viscosity (fluid lost; concentrated RBCs)
- Leukocytes accumulate along vessel margin
    ↓
MARGINATION of leukocytes (pavementing)

Acute Inflammation - CELLULAR EVENTS (Leukocyte Recruitment)

MARGINATION
(Leukocytes move to periphery of blood vessel)
    ↓
ROLLING
(selectin-mediated - loose, transient adhesion)
- Endothelial: E-selectin, P-selectin (expressed after IL-1, TNF, histamine)
- Leukocyte: sialyl-Lewis X ligand (carbohydrate)
    ↓
ADHESION (firm)
(integrin-mediated)
- Endothelial: ICAM-1, VCAM-1 (upregulated by IL-1, TNF)
- Leukocyte: CD11/CD18 (LFA-1, MAC-1) integrins
- Leukocyte integrins activated by chemokines (IL-8)
    ↓
TRANSMIGRATION (DIAPEDESIS)
- Leukocyte squeezes between endothelial cells
- PECAM-1 (CD31) on both endothelial cells and leukocytes mediates diapedesis
- Then traverses basement membrane (collagenases help degrade)
    ↓
CHEMOTAXIS
(Leukocyte migrates toward site of injury)
    ↓
PHAGOCYTOSIS AND KILLING
(See SN 1 above)
Sequence of leukocytes:
  • First 6-24 hours: Neutrophils predominate (fast, first responders)
  • After 24-48 hours: Monocytes/macrophages predominate (longer-lived, arrive later)

CHEMICAL MEDIATORS of Inflammation

I. Cell-Derived Mediators (preformed - rapid release):
MediatorSourceEffects
HistamineMast cells, basophilsVasodilation, ↑ permeability, smooth muscle spasm
Serotonin (5-HT)Platelets, enterochromaffin cellsVasodilation, ↑ permeability
Lysosomal enzymesNeutrophils, macrophagesTissue destruction, bactericidal
II. Newly Synthesised Mediators:
MediatorSourceEffects
PGI2 (prostacyclin)EndotheliumVasodilation, inhibits platelet aggregation
PGE2Many cellsVasodilation, fever, pain sensitisation
TXA2PlateletsVasoconstriction, platelet aggregation
LTB4NeutrophilsPotent chemotaxis for neutrophils
LTC4/D4/E4Mast cellsBronchoconstriction, ↑ permeability (SRS-A)
PAFMany cellsPlatelet aggregation, bronchoconstriction
III. Plasma-Derived Mediators:
SystemKey MediatorEffects
ComplementC3a, C5a (anaphylatoxins)Mast cell degranulation, chemotaxis (C5a), opsonisation (C3b)
KininBradykininPain, vasodilation, ↑ permeability
CoagulationThrombin, fibrinEndothelial activation, fibrin deposition
FibrinolysisPlasminComplement activation, fibrin degradation
IV. Cytokines:
  • IL-1, TNF-α: Principal mediators of systemic effects (fever, acute phase response, endothelial activation)
  • IL-6: Acute phase protein synthesis
  • IL-8 (CXCL8): Chemotaxis for neutrophils
  • IFN-γ: Macrophage activation
V. Nitric Oxide (NO):
  • Produced by iNOS in macrophages (large amounts - microbicidal)
  • Produced by eNOS in endothelium (small amounts - vasodilation, anti-platelet)

Acute vs Chronic Inflammation

FeatureAcute InflammationChronic Inflammation
DurationHours to daysWeeks to years
OnsetRapidGradual (or follows acute)
Predominant cellNeutrophilsMononuclear cells (macrophages, lymphocytes, plasma cells)
Tissue injuryMild (often reversible)More severe, ongoing tissue destruction
ExudateRich (protein, cells)Less prominent
Vascular changesProminentLess prominent
AngiogenesisNot typicalPresent (granulation tissue)
FibrosisAbsentPresent (progressive)
OutcomeResolution, repair, or chronicityFibrosis, granuloma, tissue destruction
ExamplesAcute appendicitis, acute lobar pneumonia, acute abscessTB, RA, Crohn disease, silicosis
Special feature-Granuloma formation (in specific chronic inflammations)

LAQ 2. Wound Healing - Regeneration/Repair, Factors, Complications, Fracture Healing, Primary/Secondary Intention

Regeneration vs Repair

RegenerationRepair (Scar Formation)
DefinitionReplacement of injured cells by cells of same typeReplacement by fibrous connective tissue (scar)
ResultFull restoration of structure and functionScar with loss of specialised function
Occurs inLabile and stable cellsAll cells; predominates in permanent cells
ExampleLiver regeneration, skin epidermisMyocardial infarction scar, skin dermis
Cell types and capacity for regeneration:
  • Labile cells (continuously dividing): skin epidermis, GI mucosa, haematopoietic cells → excellent regeneration
  • Stable cells (quiescent but can divide): hepatocytes, renal tubular cells, fibroblasts, smooth muscle → good regeneration
  • Permanent cells (cannot divide): neurons (CNS), cardiac myocytes, skeletal muscle → NO regeneration; repair by scar

Steps in Wound Repair by Scar Formation (Flowchart)

INJURY
    ↓
[Hours] Haemostasis: platelet aggregation, fibrin clot
    ↓
[Hours-Days] Acute INFLAMMATION: neutrophil influx, cleansing of debris
    ↓
[Days] MACROPHAGE PHASE: macrophages replace neutrophils;
        phagocytosis of debris; release of growth factors (EGF, PDGF, TGF-β, FGF, VEGF)
    ↓
[Days-Weeks] GRANULATION TISSUE FORMATION:
        - Angiogenesis (VEGF, FGF) → new capillaries
        - Fibroblast proliferation (PDGF, TGF-β) → collagen synthesis (Type III initially)
        - Pink granular tissue with thin-walled capillaries (histologically)
    ↓
[Weeks-Months] REMODELLING:
        - Type III collagen → Type I collagen (stronger)
        - Matrix metalloproteinases (MMPs) remodel the ECM
        - Wound contraction (myofibroblasts, α-SMA positive)
        - Scar strengthens to ~80% of original tensile strength
    ↓
MATURE SCAR
(Avascular, pale, firm collagenous tissue)

Wound Healing by Primary vs Secondary Intention

FeaturePrimary Intention (First Intention)Secondary Intention (Second Intention)
Type of woundClean, surgical incision; well-apposed edgesLarge, open wound; irregular/infected edges
InflammationMinimalIntense and prolonged
Granulation tissueSmall amountAbundant ("exuberant")
EpithelialisationBridged in 24-48 hoursTakes longer; must cover large defect
Wound contractionMinimalSignificant (myofibroblasts)
ScarNeat, linear, minimalLarge, irregular, contracted scar
Healing timeDays to 1-2 weeksWeeks to months
ExampleSutured surgical woundPressure sore, burn, infected wound

Factors Affecting Wound Healing

LOCAL factors:
  1. Infection - most important local factor; prolongs inflammation, delays healing
  2. Blood supply - ischemia severely impairs healing
  3. Foreign body - perpetuates inflammation
  4. Size and location - avascular areas (cartilage, tendons) heal poorly
  5. Mechanical stress - movement over wound delays healing
SYSTEMIC factors:
  1. Diabetes mellitus - impaired neutrophil function, microangiopathy, neuropathy
  2. Malnutrition - protein deficiency (impairs collagen synthesis); Vitamin C deficiency (cofactor for collagen hydroxylation → hydroxyprolyl and hydroxylysyl residues) → scurvy; Zinc deficiency (cofactor for MMPs)
  3. Corticosteroids - suppress inflammation, inhibit fibroblast proliferation and collagen synthesis
  4. Anaemia and hypoxia - O2 required for collagen synthesis (proline/lysine hydroxylation)
  5. Age - impaired cellular responses; reduced growth factor production
  6. Obesity - impaired blood supply to fatty tissue

Complications of Wound Healing

  1. Wound dehiscence - reopening (especially abdominal wounds; post-operative)
  2. Incisional hernia - after dehiscence of abdominal wall
  3. Hypertrophic scar - excessive collagen within wound boundaries; tends to regress
  4. Keloid - scar extends beyond wound margins; due to excess TGF-β; does NOT regress; more common in dark-skinned individuals and on face, chest, deltoid
  5. Contracture - excessive wound contraction → restricted movement (serious over joints, digits)
  6. Wound infection - bacterial contamination
  7. Ulceration - non-healing wound (due to ischemia, infection, neuropathy)
  8. Malignant change - rare; Marjolin's ulcer (SCC in chronic scar/burn)

Complications of Bone (Fracture) Healing

  1. Non-union - failure to heal (due to infection, poor immobilisation, poor blood supply, gap between fragments)
  2. Delayed union - takes longer than expected
  3. Malunion - heals in wrong position
  4. Avascular necrosis - disruption of blood supply (scaphoid, femoral head)
  5. Myositis ossificans - heterotopic ossification in muscle adjacent to fracture
  6. Fracture disease - prolonged immobilisation → joint stiffness, muscle atrophy

Fracture Healing (Sequence)

FRACTURE
    ↓
[Immediate] HAEMATOMA formation at fracture site
(torn vessels, periosteum, endosteum)
    ↓
[Days 1-5] ACUTE INFLAMMATION
Neutrophils, then macrophages; fibrin clot; growth factor release
    ↓
[Days 5-14] SOFT CALLUS (procallus) formation
- Fibroblasts and chondroblasts invade clot
- Type II collagen + cartilage bridging fracture gap (enchondral ossification)
- Periosteal cells differentiate → cartilage
- X-ray: no visible callus yet
    ↓
[Weeks 2-6] HARD CALLUS (bony callus) formation
- Woven bone laid down (by osteoblasts)
- Cartilage calcifies → replaced by woven bone
- X-ray: callus visible at 3-6 weeks
    ↓
[Months] REMODELLING
- Woven bone → lamellar bone (stronger)
- Medullary cavity restored
- Callus remodels to original bone shape (Wolff's law)
- Can take 1-2 years for complete remodelling


SECTION: Neoplasia


SN 1. Precancerous Lesions

Definition: Conditions that have a significantly higher-than-normal risk of developing into cancer. Also called premalignant lesions or lesions with dysplasia.
ConditionCancer Risk
Barrett's oesophagus (intestinal metaplasia)Oesophageal adenocarcinoma
Chronic atrophic gastritis with intestinal metaplasiaGastric carcinoma
Ulcerative colitis (>10 years duration)Colorectal carcinoma
Cervical CIN III / Severe dysplasia (HPV)Cervical squamous cell carcinoma
Leukoplakia of oral mucosaOral SCC
Bowen's disease (carcinoma in situ of skin)Skin SCC
Actinic (solar) keratosisSkin SCC
Adenomatous polyps of colonColorectal carcinoma
Xeroderma pigmentosum (DNA repair defect)Skin cancers, multiple
Hepatic cirrhosisHepatocellular carcinoma
Paget's disease of boneOsteosarcoma
Cryptorchidism (undescended testis)Testicular germ cell tumour
Li-Fraumeni syndrome (TP53 mutation)Multiple cancers
Dysplastic naevus syndromeMalignant melanoma

SN 2. Role of Tumour Markers in Diagnosis

Definition: Tumour markers are substances (proteins, hormones, enzymes, antigens) produced by tumour cells or normal cells in response to tumours, detectable in blood, urine, or tissues. They are used for diagnosis, monitoring, and prognosis - but NOT for screening in most cancers (low specificity; can be elevated in benign conditions).
MarkerCancerNormal RangeNotes
PSA (Prostate-Specific Antigen)Prostate carcinoma<4 ng/mLCan be elevated in BPH; screening controversial
AFP (Alpha-fetoprotein)Hepatocellular carcinoma; Non-seminomatous germ cell tumours (NSGCT)<10 ng/mLElevated in liver disease, pregnancy
β-hCGChoriocarcinoma; NSGCTMinimal in malesAlso made by placenta
CEA (Carcinoembryonic antigen)Colorectal, pancreatic, gastric, lung cancer<5 ng/mLNon-specific; used for monitoring
CA-125Ovarian carcinoma<35 U/mLElevated in endometriosis, pregnancy
CA 19-9Pancreatic, biliary carcinoma<37 U/mLUseful for monitoring
CA 15-3Breast cancerMonitoring only
LDHLymphoma, testicular germ cell tumoursGeneralNon-specific
CalcitoninMedullary thyroid carcinoma<10 pg/mLScreening in MEN2 families
ThyroglobulinDifferentiated thyroid carcinomaPost-thyroidectomy monitoring
S-100 proteinMelanoma, schwannomaNeural crest origin
Chromogranin ANeuroendocrine tumours (carcinoid, pheochromocytoma)Monitoring
Uses:
  1. Diagnosis: AFP in hepatocellular carcinoma; hCG in choriocarcinoma; calcitonin in medullary thyroid carcinoma
  2. Monitoring response to treatment (most common use): PSA after prostatectomy; AFP/hCG after testicular tumour chemotherapy; CEA after colorectal surgery
  3. Detecting recurrence - rising PSA after prostatectomy = recurrence
  4. Prognosis - higher AFP = worse prognosis in HCC

SN 3. Paraneoplastic Syndromes

Definition: Signs and symptoms caused by substances produced by tumour cells (hormones, peptides, antibodies) or by immune responses against tumour antigens that cross-react with normal tissues - but NOT caused by direct invasion, obstruction, or metastasis of the tumour.
SyndromeManifestationTumourMediator
HypercalcaemiaMost common paraneoplastic syndromeSCC lung, breast, renal, myelomaPTHrP (parathyroid hormone-related peptide)
SIADHHyponatraemia, water retentionSmall cell lung cancerEctopic ADH
Cushing syndromeHypertension, hyperglycaemia, obesitySmall cell lung cancer, carcinoid, pheochromocytomaEctopic ACTH
Polycythaemia↑ RBCs, plethoraRenal cell carcinoma, hepatocellular, cerebellar haemangioblastomaEctopic erythropoietin
Hypoglycaemia↓ Blood glucoseHepatocellular, fibrosarcoma, retroperitoneal tumoursIGF-2 or insulin-like peptides
Carcinoid syndromeFlushing, diarrhoea, bronchoconstriction, right heart diseaseCarcinoid tumour (with liver metastases)Serotonin (5-HT), bradykinin
Trousseau syndromeMigratory thrombophlebitisPancreatic, lung cancerMucin activates coagulation
Eaton-Lambert syndromeProximal muscle weakness (unlike myasthenia)Small cell lung cancerAnti-VGCC antibodies
Acanthosis nigricansVelvety hyperpigmented skin foldsGastric, GI, lung cancerEGF receptor activation
Hypertrophic osteoarthropathyPeriosteal new bone, clubbing, arthritisLung cancerUnknown
Cerebellar degenerationAtaxia, dysarthriaLung, breast, ovaryAnti-Yo, anti-Hu antibodies
DermatomyositisProximal muscle weakness + rashLung, GI, breastImmune-mediated
Nephrotic syndromeProteinuria, oedemaHodgkin lymphoma (membranous nephropathy)Immune complex

LAQ 1. Laboratory Diagnosis of Cancer + Chemical Carcinogenesis

Laboratory Diagnosis of Cancer

1. Histopathology (Biopsy) - Gold Standard:
  • Incisional biopsy: Sample from large lesion
  • Excisional biopsy: Complete removal of small lesion
  • Core needle biopsy: Percutaneous (breast, liver, prostate)
  • Fine-Needle Aspiration Cytology (FNAC): Aspirate cells only (no architecture); rapid, minimal invasive; good for thyroid, breast, lymph node
  • Frozen sections - intraoperative rapid diagnosis
2. Cytology:
  • Exfoliative cytology: Shed cells in secretions/washings
    • Pap smear (cervical cancer screening)
    • Sputum cytology (lung cancer)
    • Urine cytology (bladder cancer)
    • CSF cytology (CNS tumours)
3. Immunohistochemistry (IHC):
  • Antibodies to specific antigens identify cell of origin in undifferentiated tumours
  • Key markers: Cytokeratins (carcinomas), Vimentin (sarcomas), LCA/CD45 (lymphomas), S-100 (melanoma, neural), Desmin (muscle), CD30 (Hodgkin/ALCL), ER/PR/HER2 (breast cancer - guides treatment)
4. Flow Cytometry:
  • Immunophenotyping of haematologic malignancies
  • Cell cycle analysis (DNA ploidy - aneuploidy suggests malignancy)
5. Molecular/Genetic Techniques:
  • PCR: Detect specific mutations (KRAS, EGFR, BRAF), gene rearrangements (BCR-ABL in CML)
  • FISH (Fluorescence in situ hybridisation): Detect gene amplifications (HER2/neu in breast cancer) and translocations (t(9;22) in CML)
  • Comparative Genomic Hybridisation (CGH) / Next-generation sequencing (NGS): Comprehensive genomic profiling
  • BRCA1/2 mutation testing (hereditary breast/ovarian)
6. Tumour Markers (serum): As described in SN 2 above

Chemical Carcinogenesis

Definition: Cancer induction by chemical agents (carcinogens) that damage DNA.
Mechanism (Multi-step process):
INITIATION → PROMOTION → PROGRESSION

INITIATION:
Chemical carcinogen enters cell
    ↓
Metabolic activation (mainly by P450 enzymes in liver)
    ↓
ULTIMATE CARCINOGEN (electrophilic, reactive)
    ↓
Binds covalently to DNA → ADDUCTS
    ↓
If not repaired → MUTATION in proto-oncogenes or tumour suppressor genes
    ↓
Initiated cell (permanent, irreversible change)
(cell itself appears normal; does not proliferate abnormally yet)

PROMOTION:
Initiated cell exposed to PROMOTER
(not carcinogenic alone; not mutagenic; reversible)
    ↓
Clonal expansion of initiated cell
    ↓
Benign tumour or dysplastic lesion

PROGRESSION:
Additional mutations accumulate
    ↓
Malignant conversion
    ↓
Invasive cancer
Classes of Chemical Carcinogens:
ClassExamplesCancer
Polycyclic aromatic hydrocarbonsBenzo[a]pyrene (cigarette smoke, coal tar)Lung, skin
Aromatic amines2-Naphthylamine (dye industry)Bladder cancer
Alkylating agentsNitrogen mustards, cyclophosphamide (therapeutic)Secondary leukaemias
NitrosaminesN-nitrosodiethylamine (processed meats, tobacco smoke)Gastric, oesophageal cancer
Aflatoxin B1Aspergillus flavus (contaminated grain/peanuts)Hepatocellular carcinoma (+ HBV synergy)
Azo dyesβ-NaphthylamineBladder cancer
Vinyl chloridePVC manufacturingAngiosarcoma of liver
BenzeneIndustrial solventAML
AsbestosConstruction, shipbuildingMesothelioma (with crocidolite), lung cancer
ArsenicPesticides, contaminated waterSkin, lung, liver angiosarcoma

LAQ 2. Benign vs Malignant Neoplasms, Routes of Spread, Classification

Definition of Neoplasia

Neoplasia (Greek: "new growth") is an abnormal mass of tissue the growth of which exceeds and is uncoordinated with that of normal tissues and persists in the same excessive manner after cessation of the stimuli which evoked the change. It involves clonal proliferation of cells that have acquired genetic mutations in growth regulation.

Classification of Neoplasms

By behaviour: Benign vs Malignant By tissue of origin:
TissueBenignMalignant
Epithelium (squamous)Squamous papillomaSquamous cell carcinoma
Epithelium (glandular)AdenomaAdenocarcinoma
Fibrous tissueFibromaFibrosarcoma
Adipose tissueLipomaLiposarcoma
Smooth muscleLeiomyomaLeiomyosarcoma
CartilageChondromaChondrosarcoma
BoneOsteomaOsteosarcoma
Blood vesselsHaemangiomaAngiosarcoma
Lymphoid tissue-Lymphoma
Plasma cells-Multiple myeloma
MelanocytesNaevus (mole)Melanoma
Nerve sheathNeurofibromaMalignant peripheral nerve sheath tumour
Special types:
  • Teratoma - contains elements from all 3 germ layers (can be benign or malignant)
  • Hamartoma - disorganised but mature tissue indigenous to that site
  • Choristoma - normal tissue in an abnormal location

Differences: Benign vs Malignant Neoplasms

FeatureBenignMalignant
Growth rateSlowRapid (variable)
BorderWell-defined, encapsulatedIrregular, infiltrative, no capsule
DifferentiationWell-differentiated (resembles parent tissue)Poorly differentiated to anaplastic
MitosesRare; normalFrequent; atypical (tripolar, multipolar)
Nuclear featuresNormal N:C ratio↑ N:C ratio; hyperchromatic; pleomorphic nuclei
MetastasisABSENT (most important criterion)PRESENT
Local invasionNo (compresses but does not invade)Yes (invades and destroys adjacent tissue)
RecurrenceRare after excisionCommon
Effect on hostUsually local pressureLocal invasion + systemic effects
Necrosis/HaemorrhageRareCommon
VascularisationAdequateInadequate (central necrosis common)
ExamplesLipoma, uterine fibroid, thyroid adenomaCarcinoma, sarcoma, lymphoma

Routes of Spread of Malignant Neoplasms (LAQ 3 + 4)

1. Direct/Local Invasion:
  • Tumour cells invade adjacent tissues by proteolytic degradation of ECM (MMPs, cathepsins)
  • Loss of E-cadherin (loss of cell-cell adhesion) → epithelial-mesenchymal transition (EMT)
  • Example: Rectal carcinoma invading bladder; breast carcinoma invading chest wall
2. Lymphatic Spread (most common for carcinomas):
  • Tumour cells enter lymphatic channels → regional lymph nodes
  • Lymph node involvement = metastatic lymphadenopathy (hard, matted, non-tender)
  • Sentinel lymph node biopsy - first lymph node draining a tumour (if negative = node negative disease)
  • Example: Breast carcinoma → axillary nodes; Lung carcinoma → hilar/mediastinal nodes
3. Haematogenous Spread (most common for sarcomas):
  • Tumour cells enter veins (thin walls, easier than arteries)
  • Portal system → liver (GI cancers - liver most common visceral metastatic site)
  • Systemic veins → lungs (second most common metastatic site)
  • Vertebral (Batson's) venous plexus → spine, pelvis (prostate, breast, thyroid cancers)
  • Target organ tropism:
    • Liver: GI cancers, pancreas
    • Lung: Nearly any cancer (very vascular)
    • Bone: Prostate (osteoblastic/sclerotic), breast, lung, kidney, thyroid (lytic/mixed) - mnemonic: PB LKT
    • Brain: Lung, breast, melanoma, kidney, colon ("Let Me Buy Coca-Cola")
4. Transcoelomic (Seeding into body cavities):
  • Tumours penetrating peritoneum, pleura, pericardium, subarachnoid space
  • Spread along surfaces → implants throughout the cavity
  • Example: Krukenberg tumour (gastric signet ring carcinoma metastases to both ovaries via transcoelomic spread); pseudomyxoma peritonei (mucin-secreting ovarian/appendiceal tumour seeds peritoneum); malignant ascites
5. Perineural Spread:
  • Tumour grows along nerve sheaths
  • Example: Prostate cancer, head and neck cancers

LAQ 3 + 4. Metastasis - Definition, Mechanism, and Modes

Definition of Metastasis

Metastasis is the development of a secondary tumour growth discontinuous with the primary tumour, implanted at a distant site via one of the above routes of spread. It is the hallmark of malignancy and the main cause of cancer-related deaths.

Mechanism of Metastasis (The Metastatic Cascade - Flowchart)

PRIMARY TUMOUR (established)
         ↓
[Step 1] LOCAL INVASION
- Loss of E-cadherin → cells detach from neighbours
- Metalloproteinases (MMPs) degrade basement membrane & ECM
- Epithelial-Mesenchymal Transition (EMT): tumour cells acquire
  mesenchymal phenotype (spindle shape, motile, invasive)
         ↓
[Step 2] INTRAVASATION
- Tumour cells enter blood vessels or lymphatics
- Facilitated by VEGF (tumour angiogenesis) + leaky tumour vessels
         ↓
[Step 3] SURVIVAL IN CIRCULATION
- Circulating Tumour Cells (CTCs) must evade:
  → NK cell killing
  → Shear forces in blood
  → Anoikis (apoptosis from loss of matrix contact)
- May be protected by platelet coating
         ↓
[Step 4] ARREST IN DISTANT ORGAN
- CTCs arrest in capillaries (size restriction or receptor-ligand binding)
- Organ tropism determined by:
  → "Seed and Soil" hypothesis (Paget, 1889): metastatic cells (seeds) will only
    colonise organs (soil) that provide a favourable microenvironment
  → Expression of chemokine receptors (CXCR4 on breast cancer cells → CXCL12 rich in bone)
         ↓
[Step 5] EXTRAVASATION
- Tumour cells exit capillaries into target organ
         ↓
[Step 6] FORMATION OF MICROMETASTASIS
- Tumour cells survive and proliferate in new site
- May remain dormant for years (cancer dormancy)
         ↓
[Step 7] ANGIOGENESIS & COLONISATION
- Tumour induces VEGF → new blood vessels
- Establishes MACROMETASTASIS (clinically detectable secondary)

SECTION: Genetic and Paediatric Diseases


SN 1 + 2. Down's Syndrome / Trisomy 21

Definition

Down's syndrome is the most common chromosomal disorder and the most common cause of mental retardation, caused by the presence of three copies of chromosome 21 (trisomy 21).
Incidence: 1 in 700 live births (increases with maternal age: >35 years = 1 in 300; >45 years = 1 in 25)

Karyotypes

TypeMechanismProportion
Trisomy 21 (classic)Non-disjunction during meiosis I or II (mostly maternal)~95%
Translocation Down'sRobertsonian translocation: extra chr. 21 fused to chr. 14 (or 13, 22)~4% - FAMILIAL; not related to maternal age
Mosaic Down'sPost-fertilisation non-disjunction → some cells normal, some trisomy 21~1% - milder phenotype

Clinical Features

Facies (characteristic dysmorphic features):
  • Flat facial profile (flat nasal bridge)
  • Upward-slanting palpebral fissures (mongoloid slant)
  • Epicanthal folds (bilateral)
  • Brushfield spots (white/grey spots on iris periphery)
  • Protruding tongue (macroglossia + small oral cavity) and small, open mouth
  • Small, low-set ears
  • Short, broad neck with excess nuchal skin
Hands and limbs:
  • Short, stubby fingers (brachydactyly)
  • Simian crease (single transverse palmar crease) - in 50%
  • Clinodactyly (incurved 5th finger)
  • Short stature and hypotonia (floppy baby at birth)
  • Wide gap between 1st and 2nd toes
CNS:
  • Intellectual disability (IQ usually 40-60; mild to moderate)
  • Hypotonia at birth
  • Alzheimer disease in virtually ALL Down's patients by age 40 (APP gene on chr. 21 → excess amyloid precursor protein → Aβ plaques)
Cardiac (most common cause of death in childhood):
  • Congenital heart defects in 40-50%: most commonly ASD + VSD (atrioventricular septal defect / endocardial cushion defect, AVSD)
Haematological:
  • Increased risk of leukaemia: 10-20x higher risk; ALL (children), AML particularly (transient myeloproliferative disorder in newborns)
GI:
  • Duodenal atresia (double-bubble sign on X-ray)
  • Hirschsprung's disease
Endocrine:
  • Hypothyroidism (increased susceptibility)
Immunological:
  • Increased susceptibility to infections (especially respiratory)
Fertility: Females may be fertile; males almost always sterile
Diagnosis:
  • Prenatal: NIPT (non-invasive prenatal testing) - maternal blood cfDNA; NT measurement; triple/quadruple serum screen (↓AFP, ↓uE3, ↑hCG, ↑inhibin A)
  • Diagnostic: Karyotype (amniocentesis or CVS)
  • Postnatal: Karyotype from peripheral blood lymphocytes

SN 3. Klinefelter's Syndrome

Definition

Klinefelter's syndrome is the most common sex chromosome abnormality, caused by the presence of two or more X chromosomes in a phenotypic male (at least one Y chromosome present). The classic karyotype is 47,XXY.
Incidence: 1 in 660 male births; increases with maternal age

Karyotypes

KaryotypeProportionSeverity
47,XXY (classic)~80%Standard features
48,XXXYRareMore severe
48,XXYYRareTall, aggressive
Mosaic 46,XY/47,XXY~10%Milder; may be fertile

Pathogenesis

  • Extra X chromosome: X-inactivation (Barr body formation) is incomplete → one inactive Barr body visible in 47,XXY cells
  • Hypogonadism: Small testes → ↓ testosterone → clinical features
  • Number of Barr bodies = number of X chromosomes minus 1 (so 47,XXY has 1 Barr body)

Clinical Features

47,XXY (Klinefelter's)
         ↓
SMALL, FIRM TESTES (most constant finding; <2 mL)
  ↓ Testosterone          ↓ Inhibin B
         ↓                        ↓
↑ FSH, ↑ LH (hypergonadotropic)   Sertoli cell dysfunction
         ↓                        ↓
HYPOGONADISM              AZOOSPERMIA (infertility - major presenting complaint)
         ↓
TALL STATURE (due to delayed epiphyseal closure from low oestrogen)
Long legs (eunuchoid proportions): arm span > height; lower segment > upper segment
         ↓
GYNAECOMASTIA (in ~50%; due to ↑ oestrogen:testosterone ratio)
         ↓
SPARSE FACIAL, AXILLARY, PUBIC HAIR
         ↓
MILD INTELLECTUAL DISABILITY (IQ ~10-15 below siblings; mainly language-based)
         ↓
BEHAVIOURAL: Shy, poor social skills, impulsivity; increased risk of anxiety/depression
Additional associations:
  • Increased risk of breast cancer (20-50x higher than normal males due to gynaecomastia)
  • Increased risk of extragonadal germ cell tumours
  • Mitral valve prolapse
  • Systemic lupus erythematosus
  • Metabolic syndrome
Investigations:
  • Karyotype (diagnostic)
  • Hormones: ↑ FSH, ↑ LH, ↓ testosterone, ↑ oestradiol
  • Semen analysis: azoospermia
  • Testicular biopsy: hyalinisation and fibrosis of seminiferous tubules + Sertoli cell-only pattern; Leydig cell hyperplasia
Management:
  • Testosterone replacement (from adolescence onward) - develops male secondary sexual characteristics, prevents osteoporosis
  • Infertility: Testicular sperm extraction (TESE) + ICSI in some cases
  • Psychological support

All answers based primarily on Robbins, Cotran & Kumar Pathologic Basis of Disease (10th ed), with supplementation from Goldman-Cecil Medicine and Cellular & Molecular Immunology. - Orris

Give me revised answer with flow charts for the very 1st image I sent

The first image covered Pathology Paper I with these topics:
  • SN 1-4: Calcification, Apoptosis, Cellular Adaptations, Free Radicals
  • LAQ 1: Necrosis types + Caseous/Coagulative/Liquefactive necrosis
  • LAQ 2: Brown atrophy of heart
  • Immunopathology SN 1: Hypersensitivity reactions + Type I
  • Immunopathology SN 2: Amyloidosis
Here are the fully revised answers with flowcharts embedded throughout:

Pathology Paper I - Revised with Flowcharts


SECTION: Injury, Cellular Adaptations and Cellular Aging


SN 1. Types of Calcification | Dystrophic vs Metastatic

Types of Pathologic Calcification

Pathologic calcification = abnormal deposition of calcium salts in tissues. Two major forms:
PATHOLOGIC CALCIFICATION
         │
    ┌────┴────────────────────┐
    │                         │
DYSTROPHIC              METASTATIC
(dead tissue)           (normal tissue)
Normal serum Ca²⁺       Elevated serum Ca²⁺

Dystrophic Calcification - Mechanism (Flowchart)

CELL NECROSIS / INJURY
         ↓
Membrane damage → uncontrolled Ca²⁺ influx into cell
         ↓
Phospholipid-rich membrane vesicles released
         ↓
Vesicles concentrate Ca²⁺ and phosphate
         ↓
Initial crystalline nucleation (hydroxyapatite)
         ↓
Propagation → calcium deposits grow
         ↓
DYSTROPHIC CALCIFICATION
(despite normal serum Ca²⁺ levels)
Sites: Areas of coagulative, caseous, liquefactive or fat necrosis; atheromatous plaques; aging/damaged heart valves; tuberculous lymph nodes
Histology (H&E): Basophilic, amorphous, granular deposits - intracellular or extracellular. Over time: psammoma bodies (lamellated concentric calcifications) - seen in papillary thyroid carcinoma, meningioma, serous papillary ovarian carcinoma.
Dystrophic calcification aortic valve
Dystrophic calcification of the aortic valve - Robbins Pathology

Metastatic Calcification - Mechanism (Flowchart)

SYSTEMIC HYPERCALCAEMIA
(hyperparathyroidism / bone destruction / vit D excess / renal failure)
         ↓
Elevated serum Ca²⁺ × phosphate product
         ↓
Supersaturation of interstitial fluids
         ↓
Precipitation of calcium salts in NORMAL tissues
(preferentially in tissues that lose acid → ↑ local pH)
         ↓
METASTATIC CALCIFICATION
Sites: Gastric mucosa, kidneys (nephrocalcinosis), lungs, systemic arteries, cornea

Dystrophic vs Metastatic - Comparison Table

FeatureDystrophicMetastatic
Serum calciumNormalElevated
Tissue involvedDead / necroticNormal / viable
Calcium metabolismNormalDisturbed
CauseLocal injury/necrosisSystemic hypercalcaemia
ExamplesTB lymph node, atheroma, damaged valvesHyperparathyroidism, renal failure, bony metastases
Clinical significanceMarker of prior necrosisIndicates systemic metabolic disease

SN 2. Apoptosis - Definition, Examples, Morphological Changes, Mechanisms, Physiological and Pathological Causes

Definition

Apoptosis is a programmed, energy-dependent, caspase-mediated form of cell death in which a cell activates an intrinsic suicide programme. The plasma membrane remains intact throughout; apoptotic bodies are formed and rapidly phagocytosed - no inflammation occurs.

Morphological Changes (Sequence)

NORMAL CELL
     ↓
1. CELL SHRINKAGE
   (cytoplasm condenses; organelles tightly packed)
     ↓
2. CHROMATIN CONDENSATION (PYKNOSIS)
   (chromatin aggregates peripherally under nuclear membrane)
     ↓
3. NUCLEAR FRAGMENTATION (KARYORRHEXIS)
   (nucleus breaks into fragments)
     ↓
4. CYTOPLASMIC BLEBBING
   (irregular budding of plasma membrane)
     ↓
5. APOPTOTIC BODY FORMATION
   (membrane-bound fragments containing organelles ± nuclear debris)
     ↓
6. PHAGOCYTOSIS by macrophages / neighbouring cells
   (no leakage of contents → NO INFLAMMATION)
Key distinction from necrosis: Membrane integrity maintained; no inflammatory response; ordered process vs necrosis which is chaotic/uncontrolled.

Mechanisms / Pathways of Apoptosis

INTRINSIC (Mitochondrial) Pathway

STRESS SIGNALS
(DNA damage, oxidative stress, ER stress, growth factor withdrawal)
         ↓
BH3-only proteins activated (BAD, BIM, BID, PUMA, NOXA)
         ↓
BH3-only proteins → inhibit anti-apoptotic BCL2/BCL-XL
                  → directly activate pro-apoptotic BAX/BAK
         ↓
BAX/BAK oligomerise in outer mitochondrial membrane
         ↓
CYTOCHROME C leaks into cytosol
         ↓
Cytochrome c + APAF-1 → APOPTOSOME
         ↓
Activates CASPASE-9 (initiator caspase)
         ↓
Activates CASPASE-3 (executioner caspase)
         ↓
APOPTOSIS (DNA fragmentation, membrane blebbing, etc.)

BCL2 family roles:
Anti-apoptotic: BCL2, BCL-XL, MCL1 → block cytochrome c release
Pro-apoptotic: BAX, BAK → pore formation
BH3-only sensors: BAD, BIM, BID, PUMA, NOXA → activate BAX/BAK

EXTRINSIC (Death Receptor) Pathway

FAS LIGAND (FasL) binds FAS (CD95) receptor
  OR  TNF binds TNFR1
         ↓
Receptor trimerisation → recruitment of FADD
(Fas-Associated Death Domain protein)
         ↓
Activates CASPASE-8 (initiator)
         ↓
      ┌──┴──────────────────────┐
      ↓                         ↓
Direct activation          Cleavage of BID (BH3-only)
of CASPASE-3                    ↓
                           tBID activates BAX/BAK
                           → cross-talks with intrinsic pathway
                                ↓
                    Caspase-9 → Caspase-3
         ↓
APOPTOSIS

Physiological Causes (Normal Programmed Cell Death)

SituationExample
EmbryogenesisInterdigital web removal; organ morphogenesis
Hormone withdrawalEndometrial shedding (menstruation); breast involution post-lactation
Immune regulationDeletion of self-reactive lymphocytes in thymus (negative selection)
Maintaining cell numberIntestinal crypt cell turnover
Post-immune responseDeath of effector T and B lymphocytes after infection is cleared

Pathological Causes

ConditionMechanism
DNA damage (radiation, chemotherapy)p53 activates BH3-only proteins → intrinsic pathway
Viral infectionsHepatitis B/C → hepatocyte apoptosis
Neurodegenerative diseasesER stress from misfolded proteins → UPR → apoptosis
Duct obstructionPancreatic/salivary duct obstruction → gland cell apoptosis
Myocardial ischaemiaApoptosis at border zone of infarct
Cytotoxic T cell killingExtrinsic pathway (perforin-granzyme and Fas-FasL)

SN 3. Metaplasia, Hypertrophy, Hyperplasia, and Atrophy

Cellular Adaptations Overview (Flowchart)

CELL UNDER STRESS
         │
    ┌────┴────────────────────────────────────────┐
    │           │              │                   │
ATROPHY   HYPERTROPHY   HYPERPLASIA           METAPLASIA
(↓ size)  (↑ size)      (↑ number)            (change in type)
         │           │              │                   │
  Reduced        Increased      Cell            One adult
  workload/      demand,        division        cell type →
  nutrition/     hormones       stimulated      another adult
  denervation    stimulate      by growth       cell type
                 protein        factors/
                 synthesis      hormones

ATROPHY

Definition: Reduction in the size of a cell (and organ) due to loss of cell substance - decreased protein synthesis + increased degradation.
Mechanisms:
ATROPHIC STIMULUS
(disuse, denervation, ischaemia, malnutrition, ageing)
         ↓
     ┌───┴────────────────────┐
     ↓                        ↓
↓ Protein synthesis    ↑ Protein degradation
(↓ IGF-1, ↓ nutrients)  (Ubiquitin-proteasome pathway)
     └───────────┬────────────┘
                 ↓
         AUTOPHAGY
(cell digests own organelles via autophagosomes)
         ↓
Accumulation of lipofuscin (residual bodies)
         ↓
SMALLER CELL / ORGAN (atrophy)
Examples:
  • Physiologic: brain atrophy in old age; uterus after menopause
  • Pathologic: limb muscle in plaster cast (disuse); muscle after nerve section (denervation); thyroid after loss of TSH; kidney with reduced blood supply; cancer cachexia

HYPERTROPHY

Definition: Increase in size of cells → enlarged organ. No increase in cell number. Occurs in cells incapable of division (cardiac myocytes, skeletal muscle).
Mechanism (Cardiac Hypertrophy):
INCREASED WORKLOAD (hypertension, valve stenosis)
         ↓
Mechanical sensors in cardiomyocyte detect load
         ↓
Activation of signalling pathways:
- PI3K/AKT pathway (physiologic - exercise)
- G-protein-coupled receptors (pathologic - angiotensin II, ET-1, α-adrenergic)
         ↓
Transcription factors activated: GATA4, NFAT, MEF2
         ↓
↑ Contractile protein synthesis
Switch: α-myosin → β-myosin heavy chain (slower, economical)
↑ Atrial natriuretic peptide (↓ blood volume/pressure)
         ↓
LARGER CARDIOMYOCYTES → LVH
(Compensated initially; eventually decompensation → heart failure)
Examples:
  • Physiologic: gravid uterus (smooth muscle + hypertrophy); bodybuilder's biceps; cardiac hypertrophy in trained athletes
  • Pathologic: LVH in hypertension; right ventricular hypertrophy in pulmonary hypertension

HYPERPLASIA

Definition: Increase in number of cells in a tissue → enlarged organ. Occurs only in cells capable of division. Often concurrent with hypertrophy.
Mechanism:
GROWTH FACTOR / HORMONAL STIMULUS
(EGF, HGF, oestrogen, TSH, ACTH, DHT)
         ↓
Binding to cell surface receptors
         ↓
Signal transduction (RAS-MAPK, PI3K-AKT)
         ↓
G1 → S phase transition (cyclin D/CDK4 activated)
         ↓
Stem cell proliferation + daughter cell differentiation
         ↓
INCREASED CELL NUMBER (Hyperplasia)
Examples:
  • Physiologic: Breast glandular hyperplasia during pregnancy; liver regeneration after partial hepatectomy (compensatory); thyroid hyperplasia in iodine deficiency (goitre)
  • Pathologic: Endometrial hyperplasia (excess oestrogen); BPH (benign prostatic hyperplasia, due to DHT); psoriasis; adrenal cortical hyperplasia (excess ACTH)

METAPLASIA

Definition: Reversible change where one adult cell type is replaced by another adult cell type - usually more resistant to the stress causing the change.
Mechanism:
CHRONIC IRRITATION / STRESS
(smoking, reflux, stone, vitamin A deficiency)
         ↓
Reprogramming of LOCAL TISSUE STEM CELLS
(not transdifferentiation of existing differentiated cells)
         ↓
Stem cells produce new cell lineage
(driven by altered gene expression: e.g., CDX2 in Barrett's)
         ↓
METAPLASTIC EPITHELIUM
(better suited to survive the stress; but functional cost)
         ↓
If stimulus persists → DYSPLASIA → CARCINOMA
Types:
TypeExampleCancer Risk
Columnar → SquamousSmoker's bronchus; cervical ectropion; stones in ductsSCC (e.g., lung SCC in smokers)
Squamous → ColumnarBarrett's oesophagus (GERD → intestinal metaplasia)Oesophageal adenocarcinoma
Connective tissueMyositis ossificans (bone in muscle after haematoma)None
Squamous metaplasia in bronchus
Squamous metaplasia in bronchus (smoker) - Robbins Pathology

SN 4. Free Radicals and Free Radical-Induced Cell Injury

Definition

Free radicals are molecules with a single unpaired electron in an outer orbit, making them highly reactive. They attack proteins, lipids, DNA in autocatalytic chain reactions.
Most important in pathology: Reactive Oxygen Species (ROS) - O₂•⁻ (superoxide), H₂O₂ (hydrogen peroxide), •OH (hydroxyl radical - most destructive).

Generation of Free Radicals (Flowchart)

SOURCES OF FREE RADICAL GENERATION:
         │
    ┌────┼──────────────────────────────────────┐
    ↓    ↓                ↓                      ↓
Normal  Radiation        Activated           Drug/Chemical
Mitochondrial (UV, X-ray)  Leukocytes         metabolism
respiration      ↓        (NADPH oxidase)     (CCl₄ → •CCl₃)
    ↓        Water        → O₂•⁻                   ↓
O₂ partially  hydrolysis       ↓               P450 enzymes
reduced →    → •OH        H₂O₂                generate radicals
O₂•⁻                          ↓
    ↓               + Fe²⁺ (Fenton reaction):
H₂O₂           H₂O₂ + Fe²⁺ → Fe³⁺ + •OH + OH⁻
    ↓           (MOST DAMAGING radical)
•OH (via
 Fenton rxn)

Antioxidant Defence Systems

FREE RADICALS GENERATED
         ↓
DEFENCE MECHANISMS:
    ├─ Superoxide dismutase (SOD): O₂•⁻ + O₂•⁻ → H₂O₂ + O₂
    ├─ Catalase: H₂O₂ → H₂O + O₂
    ├─ Glutathione peroxidase: H₂O₂ + 2GSH → GSSG + 2H₂O
    ├─ Vitamins E (membrane), A, C (aqueous) - scavengers
    └─ Transferrin, ceruloplasmin - sequester iron/copper
         ↓
If defence is OVERWHELMED:
OXIDATIVE STRESS

Mechanisms of Free Radical-Induced Cell Injury

EXCESS FREE RADICALS (Oxidative Stress)
         │
    ┌────┼────────────────────────────────┐
    ↓    ↓                ↓               ↓
LIPID    PROTEIN       DNA DAMAGE    APOPTOSIS
PEROXIDATION OXIDATION                ACTIVATION
    ↓         ↓             ↓              ↓
•OH attacks  Amino acid   Single/double  Caspase
double bonds side chain    strand breaks  cascade
in membrane  oxidation     in DNA        activated
polyunsaturated   ↓             ↓         (low doses)
fatty acids  Enzyme active  DNA adducts
    ↓        site disrupted  → mutations
Lipid peroxide  Cross-linking  → cancer,
    ↓        of proteins       aging
New radicals ↓
generated   Proteasomal
(chain rxn)  degradation
    ↓        of misfolded
Membrane     proteins
damage:
↑ permeability,
organelle dysfunction,
cell death (NECROSIS
at high doses)

Clinical Conditions Caused by Free Radical Injury

ConditionMechanism
Ischaemia-reperfusion injuryBurst of ROS on reperfusion; mitochondrial dysfunction
Chemical toxicity (CCl₄)CYP450 converts CCl₄ → •CCl₃ → hepatic necrosis
Radiation injuryIonising radiation → •OH → DNA damage
AtherosclerosisLDL oxidation by ROS → foam cell formation
AgingCumulative oxidative DNA damage
Oxygen toxicity (neonates)Excess O₂ → ROP, BPD
Paraquat poisoningGenerates O₂•⁻ → pulmonary fibrosis
CarcinogenesisOxidative DNA damage → oncogene activation

LAQ 1. Necrosis - Clinical Scenario, Definition, Types, Caseous Morphology, Coagulative vs Liquefactive

Clinical Scenario Link

Patient 1: Diabetic, pale dry leg ulcer
    → Ischaemia (arterial occlusion in atherosclerosis)
    → Tissue preserved but dead → COAGULATIVE NECROSIS (dry gangrene)

Patient 2: TB patient, cheesy lung lesion
    → Mycobacterium tuberculosis → granulomatous inflammation
    → CASEOUS NECROSIS

Patient 3: Stroke → brain liquefaction
    → Cerebral ischaemia in neuron-rich tissue
    → LIQUEFACTIVE NECROSIS (brain always liquefies)

Definition of Necrosis

Necrosis is a form of cell death caused by exogenous injury (ischaemia, toxins, infection, trauma) in which cell swelling, membrane rupture, and leakage of intracellular contents lead to inflammatory response in surrounding tissue. It is uncontrolled, unlike apoptosis.

General Morphological Features of Necrotic Cells

Cytoplasmic changes:
  • Eosinophilia (↑ eosin binding due to denatured proteins + loss of RNA)
  • Vacuolated, moth-eaten cytoplasm
  • Myelin figures (whorled phospholipid precipitates from degraded membranes)
Nuclear changes (3 patterns):
NUCLEAR CHANGES IN NECROSIS:

1. KARYOLYSIS: Basophilia fades (DNase degrades DNA)
              Nucleus ghost-like → disappears

2. PYKNOSIS: Nuclear shrinkage + increased basophilia
            (chromatin condenses into dense mass)

3. KARYORRHEXIS: Pyknotic nucleus fragments
                Nuclear debris scattered in cytoplasm

→ After 1-2 days: nucleus COMPLETELY DISAPPEARS

Types of Necrosis - Summary Table

TypeKey FeatureGrossMicroExample
CoagulativeArchitecture preserved; ghost cellsFirm, pale, dryEosinophilic cells with no nuclei; architecture intactRenal, cardiac, splenic infarct
LiquefactiveComplete dissolution; fluid cavitySoft, fluid, cavityNo architecture; fluid + debris + leukocytesBrain infarct; pyogenic abscess
CaseousCheese-like; granulomaSoft, yellow-white, cheesyNo architecture; acellular granular debris + granulomaTuberculosis
FatSaponification (chalky white)White chalky depositsFat cells replaced by shadowy outlines; calcium soapsAcute pancreatitis; breast trauma
FibrinoidPink homogeneous fibrin-like materialNot grossly distinctiveVessel wall necrosis; fibrin + immune complexesMalignant hypertension; vasculitis; PAN
GangrenousClinical term (not true histologic type)Dry = coagulative; Wet = + liquefactiveDepends on typeDiabetic foot (dry/wet gangrene)

Caseous Necrosis - Morphology in Detail

Gross appearance:
CASEOUS NECROSIS (Gross):

Soft, friable, CHEESE-LIKE material
Colour: Yellow-white (like dry crumbled cottage cheese)
"Caseous" from Latin: caseus = cheese
Enclosed in FIBROUS CAPSULE (granuloma wall)
Classic site: TB lymph node, TB lung lesion
Microscopic appearance:
CASEOUS NECROSIS (Micro):

CENTRAL ZONE:
┌──────────────────────────────────────────────┐
│ ACELLULAR, GRANULAR, EOSINOPHILIC DEBRIS     │
│ - Complete loss of all tissue architecture   │
│ - No ghost cell outlines (unlike coagulative)│
│ - Amorphous pink material on H&E             │
└──────────────────────────────────────────────┘
            ↑ surrounded by ↑

PERIPHERAL ZONE (GRANULOMA):
┌──────────────────────────────────────────────────┐
│ EPITHELIOID MACROPHAGES                          │
│ (activated macrophages: pale, abundant cytoplasm;│
│  vesicular nuclei; elongated - look like         │
│  epithelial cells)                               │
│                                                  │
│ LANGHANS GIANT CELLS                             │
│ (fused macrophages; 10-50 nuclei arranged in     │
│  horseshoe/peripheral pattern at cell rim)       │
│ ← specific to TB and related granulomas          │
│                                                  │
│ LYMPHOCYTES (peripheral cuff)                    │
│ PLASMA CELLS (occasional)                        │
│                                                  │
│ Later: FIBROSIS + DYSTROPHIC CALCIFICATION       │
└──────────────────────────────────────────────────┘
Caseous necrosis TB
Caseous necrosis in tuberculosis lung - Robbins Pathology

Coagulative Necrosis - Detail

Mechanism:
ISCHAEMIA (arterial occlusion → O₂ deprivation)
         ↓
ATP depletion → cell swelling → membrane damage
         ↓
PROTEIN DENATURATION
(both structural proteins AND proteolytic enzymes denatured)
         ↓
Enzymes cannot digest the dead cells
         ↓
Cell shape PRESERVED for days
("Ghost cells" / "tombstone cells")
Architecture maintained
         ↓
Eventually leukocytes arrive (days later) and
lysosomal enzymes degrade the dead cells
         ↓
Absorbed → SCAR FORMS
Gross: Firm, pale/yellow-white, wedge-shaped (kidney, spleen), well-demarcated. Dry in character.
Microscopy: Intensely eosinophilic cells with absent nuclei but preserved cellular outlines (ghost cells). Inflammatory infiltrate at periphery.
Exceptions: Brain ischaemia NEVER causes coagulative necrosis - it always causes liquefactive (because brain is rich in hydrolytic enzymes and has poor structural support).
Coagulative necrosis kidney
Coagulative necrosis: wedge-shaped renal infarct - Robbins Pathology

Liquefactive Necrosis - Detail

Mechanism:
ISCHAEMIA TO BRAIN
    OR
BACTERIAL (PYOGENIC) INFECTION
         ↓
ENZYMATIC DIGESTION dominates over denaturation
(Brain: rich in hydrolytic enzymes + poor structural protein support)
(Bacteria: secrete proteolytic enzymes + recruit neutrophils)
         ↓
Neutrophils/macrophages release lysosomal enzymes
         ↓
Complete dissolution of ALL tissue components
- No ghost cells
- No architectural preservation
         ↓
FLUID-FILLED CAVITY
(cerebral infarct → cystic cavity)
(bacterial infection → PUS = liquefied dead tissue + dead neutrophils)
Gross: Soft, fluid, cavity formation. Brain stroke: cystic cavity; Abscess: pus-filled.
Microscopy: Complete loss of architecture; fluid, cellular debris, leukocytes; macrophages with engulfed debris (gitter cells in brain).
Liquefactive necrosis brain
Liquefactive necrosis: cerebral infarct - Robbins Pathology

Coagulative vs Liquefactive - Direct Comparison

FeatureCoagulative NecrosisLiquefactive Necrosis
Tissue architecturePreserved (ghost cells)Completely lost
Enzymatic digestionInhibited (enzymes denatured)Dominant
ConsistencyFirm, drySoft, fluid
AppearancePale, firm, dry infarctFluid-filled cavity / pus
Primary mechanismProtein denaturationEnzymatic digestion
SitesAll solid organs EXCEPT brainBrain; pyogenic abscesses
CauseIschaemia (arterial occlusion)Brain ischaemia; pyogenic bacteria
ExamplesMyocardial infarct, renal infarctStroke, lung abscess, brain abscess
OutcomeScar after resolutionCyst / fibrous wall (abscess)

LAQ 2. Atrophy - Definition, Morphology and Causes of Brown Atrophy of the Heart

Definition

Atrophy is defined as a reduction in the size of a cell caused by loss of cell substance. When sufficient cells are atrophied, the entire organ shrinks.

Brown Atrophy of the Heart - Pathogenesis (Flowchart)

ADVANCED AGE / CACHEXIA / CHRONIC ILLNESS
         ↓
Reduced workload on heart
(↓ cardiac output demand, muscle mass loss)
         ↓
Autophagy activated in cardiomyocytes
(intracellular organelles digested by lysosomes)
         ↓
Incomplete lysosomal digestion → LIPOFUSCIN
(oxidised lipid-protein residues accumulate
 as indigestible brown granules)
         ↓
LIPOFUSCIN accumulates in perinuclear cytoplasm
         ↓
Combined with overall cell shrinkage:
BROWN ATROPHY
(macroscopic brown discolouration + small heart)

Gross Morphology

BROWN ATROPHY HEART (Gross):

Normal heart (350-400g) → REDUCED in weight and size
Colour: BROWN (instead of normal reddish-brown)
         ↓
Coronary arteries appear TORTUOUS and DILATED
relative to the shrunken myocardium
(vessel length unchanged, heart shrinks → redundant tortuous vessels)
         ↓
Epicardial fat: may be gelatinous/serous atrophy
(fat replaced by fluid in severe cachexia)
         ↓
Cut section: Smaller, firmer myocardial fibres

Microscopic Morphology

CARDIOMYOCYTES: Smaller diameter, elongated
NUCLEI: Smaller, darker (hyperchromatic)

LIPOFUSCIN GRANULES:
→ Yellow-brown perinuclear pigment granules
→ "Wear and tear" or "aging" pigment
→ Stains: Sudan black positive, PAS positive
          Autofluorescent under UV light
          Prussian blue NEGATIVE (not iron)
→ Represents incomplete lysosomal digestion
   of oxidised lipids and proteins over lifetime

MYOFIBRILS: Reduced in number
INTERSTITIAL FIBROSIS: May be present
NO INFLAMMATORY INFILTRATE (not inflammatory)

Causes of Brown Atrophy of the Heart

CauseMechanism
Advanced age (Senile atrophy)Most common; normal aging → progressive lipofuscin accumulation + cell loss
Cancer cachexiaTNF-α, IL-1, IL-6 from tumour → ↑ protein catabolism; starvation of nutrients
Chronic debilitating illnessTB, AIDS, CHF, COPD → generalised wasting
Severe starvation/malnutritionInadequate caloric intake → protein catabolism
Prolonged immobilityDisuse → reduced cardiac demand
Hypopituitarism↓ growth hormone, ↓ thyroid hormone → reduced anabolic stimulation
Key memory point: Lipofuscin is the BROWN pigment in brown atrophy. It is a "ceroid pigment" and marker of oxidative damage accumulation.

IMMUNOPATHOLOGY


SN 1. Hypersensitivity Reactions - Classification + Type I in Detail

Definition

Hypersensitivity reactions are exaggerated or inappropriate immune responses to an antigen that cause tissue damage.

Classification (Gell & Coombs)

HYPERSENSITIVITY REACTIONS
         │
    ┌────┼──────────────────────────────────────────────┐
    ↓    ↓                ↓                              ↓
TYPE I  TYPE II        TYPE III                    TYPE IV
(IgE)   (IgG/IgM       (Immune                   (T-cell
Immediate cytotoxic)    complex)                  Delayed)
Mast cell Cell surface/ Soluble Ag-Ab             CD4+ or CD8+
degranulation matrix Ag  complexes                T cells
    ↓         ↓             ↓                          ↓
Minutes   Complement   Complement +               24-72 hours
          + NK cells   neutrophils
    ↓         ↓             ↓                          ↓
Anaphylaxis, Haemolytic Serum sickness,        Contact
asthma,    anaemia,    SLE, post-strep          dermatitis,
urticaria  Goodpasture GN, Arthus rxn          tuberculin
                                               test, Type 1 DM

Type I Hypersensitivity - Detailed Flowchart

Phase 1: SENSITISATION (First Exposure - No Symptoms)

FIRST EXPOSURE TO ALLERGEN (antigen)
         ↓
Antigen processed by APCs (dendritic cells)
         ↓
TH2 CD4+ T cells activated
(IL-4 producing environment favours TH2 differentiation)
         ↓
TH2 cells produce:
├─ IL-4 → B cell class switching to IgE
├─ IL-5 → Eosinophil recruitment/activation
└─ IL-13 → Mucus secretion, smooth muscle contraction
         ↓
IgE produced by plasma cells
         ↓
IgE binds to FcεRI receptors on MAST CELLS and BASOPHILS
(HIGH AFFINITY receptor - mast cells coated with IgE)
         ↓
SENSITISED MAST CELLS (no symptoms yet)

Phase 2: EFFECTOR PHASE (Re-exposure - Immediate Reaction, within minutes)

RE-EXPOSURE TO SAME ALLERGEN
         ↓
Allergen CROSS-LINKS IgE molecules on mast cell surface
(must bind ≥2 IgE molecules simultaneously)
         ↓
FcεRI aggregation → signal transduction
         ↓
MAST CELL DEGRANULATION
         │
    ┌────┴─────────────────────────────────────────────┐
    ↓                      ↓                            ↓
PREFORMED           NEWLY SYNTHESISED           CYTOKINES
MEDIATORS            MEDIATORS                  (over hours)
(released           (minutes-hours)
immediately)
    ↓                      ↓                            ↓
HISTAMINE          LEUKOTRIENES (AA pathway)     TNF-α
(most important)   LTC4, LTD4, LTE4            IL-4, IL-5
→ vasodilation     (SRS-A, 1000x >histamine    IL-13
→ ↑ permeability   in bronchoconstriction)      ↓
→ smooth muscle    PGD2 (prostaglandin)        Recruit
  contraction      → bronchoconstriction       eosinophils,
→ mucus secretion  PAF (platelet activating    basophils,
                   factor)                     TH2 cells
SEROTONIN          → platelet aggregation      → LATE PHASE
HEPARIN
TRYPTASE
EOSINOPHIL
CHEMOTACTIC
FACTOR

Phase 3: LATE PHASE REACTION (2-8 hours, persisting 24 hours)

Mast cell cytokines (TNF-α, IL-5) recruit:
EOSINOPHILS, BASOPHILS, NEUTROPHILS, TH2 CELLS
         ↓
Eosinophils release:
- Major Basic Protein (MBP) → tissue damage
- Eosinophil Peroxidase (EPO)
- Eosinophil Cationic Protein (ECP)
- IL-3, IL-5, GM-CSF (amplify further eosinophil production)
         ↓
PROLONGED bronchoconstriction, oedema, mucus production
(this phase explains SUSTAINED ASTHMA attacks)

Clinical Manifestations of Type I Hypersensitivity

Target OrganAllergen RouteManifestation
SystemicIV or widespreadAnaphylaxis - urticaria, angioedema, bronchospasm, hypotension, shock (life-threatening)
LungInhaledAsthma - bronchoconstriction, wheezing, dyspnoea
Nasal mucosaInhaledAllergic rhinitis - sneezing, watery discharge, nasal obstruction
SkinContact/systemicUrticaria (hives), Angioedema - wheals, flares
GIIngestedNausea, vomiting, diarrhoea, cramping
EyeInhaled/contactAllergic conjunctivitis - itching, redness

SN 2. Amyloidosis - Clinical Scenario, Definition, Classification, Molecular Structure, Special Stains

Clinical Scenario Analysis

Patient 1: RA (long-standing) + nephrotic syndrome + hepatosplenomegaly
           + spleen with "pale tapioca-like nodules"
           → SECONDARY (AA) AMYLOIDOSIS
           (chronic inflammatory disease → SAA protein → AA amyloid deposits in kidney, spleen, liver)

Patient 2: Multiple myeloma + restrictive cardiomyopathy
           + Congo red → apple-green birefringence
           → PRIMARY (AL) AMYLOIDOSIS
           (plasma cell dyscrasia → light chains → AL amyloid deposits in heart, kidney, tongue)

Definition

Amyloidosis is a group of diseases caused by extracellular deposition of insoluble fibrillar proteins (amyloid) in tissues. All amyloid fibrils share the same cross-beta pleated sheet conformation which confers resistance to proteolysis and pathognomonic staining properties.

Classification (Flowchart)

AMYLOIDOSIS
         │
    ┌────┴─────────────────────────────────────────────┐
    ↓                    ↓                              ↓
PRIMARY (AL)       SECONDARY (AA)              HEREDOFAMILIAL
    ↓                    ↓                              ↓
Precursor:          Precursor:                 Precursor:
Immunoglobulin      Serum Amyloid A            Transthyretin (ATTR)
LIGHT CHAINS        (SAA - acute               Fibrinogen Aα chain
(λ > κ)             phase protein)             Others
    ↓                    ↓                              ↓
Associated with:    Associated with:           Associated with:
Multiple myeloma    RHEUMATOID ARTHRITIS       Familial amyloid
Waldenström's      Chronic infections          polyneuropathy
monoclonal         (TB, bronchiectasis,        Familial
gammopathy         osteomyelitis)              Mediterranean fever
MGUS               IBD, Ankylosing            (AA type in FMF)
                   spondylitis                 Senile systemic
                                               amyloidosis (ATTR
                                               in elderly hearts)
    ↓                    ↓                              ↓
Deposits in:        Deposits in:               Deposits in:
Heart               KIDNEY (most               Heart (ATTR-CA)
Kidney              common → nephrotic)         Peripheral nerves
Tongue (macro-      LIVER (hepato-             Carpal tunnel
 glossia)           splenomegaly)
GI tract            SPLEEN (sago/
Peripheral nerves   lardaceous)
Skin (waxy)         Adrenals
Other amyloid types:
  • Aβ amyloid (APP-derived) → Alzheimer disease (senile plaques)
  • β₂-microglobulin amyloid → long-term haemodialysis (carpal tunnel syndrome)
  • Calcitonin-derived → Medullary thyroid carcinoma

Molecular Structure of Amyloid

AMYLOID FIBRIL STRUCTURE:

Precursor protein (soluble, native conformation)
         ↓
MISFOLDING (abnormal processing, overproduction)
         ↓
BETA-SHEET CONFORMATION adopted
(antiparallel β-pleated sheet structure)
         ↓
Individual fibrils: NON-BRANCHING, 7.5-10 nm diameter
Composed of: β-pleated sheets running perpendicular to fibril axis
         ↓
CROSS-BETA PATTERN (X-ray diffraction signature)
         ↓
Fibrils arranged in bundles → macroscopic deposits
         ↓
Also contains:
- Serum Amyloid P (SAP) component - all types
- Apolipoprotein E - all types
- Glycosaminoglycans (heparan sulphate) - all types
These non-fibril components stabilise the deposit

RESULT: INSOLUBLE, RESISTANT TO PROTEOLYSIS
→ Deposits accumulate progressively → organ damage

Special Staining for Amyloid

SPECIAL STAINS FOR AMYLOID:

1. CONGO RED (most important / pathognomonic)
   └─ Routine light: SALMON PINK / APPLE RED colour
   └─ Polarised light: APPLE-GREEN BIREFRINGENCE ← PATHOGNOMONIC
   (due to ordered beta-pleated sheet binding Congo red dye
    and rotating polarised light)

2. CRYSTAL VIOLET (Metachromatic stain)
   └─ Amyloid stains RED/VIOLET against blue background
   (metachromasia = colour different from the dye used)

3. THIOFLAVIN T or S
   └─ FLUORESCENCE under UV light
   └─ Used for small deposits and frozen sections

4. PERIODIC ACID-SCHIFF (PAS)
   └─ Weakly positive (glycoprotein component)

5. ELECTRON MICROSCOPY
   └─ Fibrils: non-branching, 7.5-10 nm diameter
   └─ Beta-sheet confirmed by X-ray diffraction (CROSS-BETA pattern)

Morphology of Amyloid Deposits in Key Organs

Spleen (matches the case - "tapioca-like nodules"):
SAGO SPLEEN (most common in AA amyloidosis):
- Amyloid in WHITE PULP (follicles)
- Gross: Small, grey/translucent tapioca/sago grain-like
         nodules = "tapioca appearance" (matches the case!)
- Histology: Amyloid replacing lymphoid follicles
         ↓
         vs.
LARDACEOUS SPLEEN (advanced/severe):
- Amyloid in RED PULP (diffuse)
- Gross: Large, firm, waxy, pale/greyish, "lard-like"
- Histology: Amyloid diffusely replacing red pulp sinusoids
Kidney:
  • Glomerular mesangium + GBM → nephrotic syndrome (massive proteinuria, oedema)
  • Tubular basement membrane deposits
  • Kidney: enlarged, pale, waxy ("large white kidney")
Heart (AL amyloidosis):
  • Restrictive cardiomyopathy (stiff, non-compliant ventricles)
  • Amyloid between myofibrils
  • Echo: "sparkling" granular echogenicity of myocardium
Liver:
  • Deposits in space of Disse (between hepatocytes and sinusoids) and portal areas
  • Hepatomegaly, elevated ALP, rarely liver failure

All answers based on Robbins, Cotran & Kumar Pathologic Basis of Disease and Cellular & Molecular Immunology. - Orris

Make a colour graded PDF of all the data except for the data of 1st image use data which you created afterwards for 1st image

Reading File
Running Command

mkdir -p /tmp/workspace/pathology-pdf && ls /tmp/workspace/

Make pdf

Running Command

mkdir -p /tmp/workspace/pathology-pdf && ls /tmp/workspace/pathology-pdf/

This is a shared conversation. Sign in to Orris to start your own chat.